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Abstract:  
The present study is initiated to explore the potential implication of 
developmental signaling in AEC I injury, acute inflammatory response, and host 
defense against pathogen invasion during the pathogenesis of ALI/ARDS.  
 
We demonstrated that P2X7R induced AEC I death by suppressing Wnt/β-
catenin signaling through activating GSK-3β and proteasome. On the other hand, 
Wn3a overrides the effect of P2X7R on inhibiting Wnt/β-catenin signaling to 
prevent the AEC I death and restricts the severity of ALI/ARDS. Our study on 
Wnt/β-catenin signaling and P2X7R-mediated purinergic signaling provides 
insights for future drug development and new therapeutic strategies to limit AEC I 
damage in ALI/ARDS patients. 
 
Furthermore, we identified platelet-derived Dkk1 as the major Wnt 
antagonist, contributing to the depression of Wnt/β-catenin signaling during 
ALI/ARDS. Intratracheal administration of Wnt3a or neutralization of Dkk1 
inhibited neutrophil influx into alveolar airspace of the injured lungs potentially 
through the attenuated ICAM-1/VCAM-1 mediated adhesion of inflammatory 
cells. We reported for the first time a role of Wnt/β-catenin signaling in 
modulating inflammatory response, and a functional communication between 
platelets and AEC during ALI/ARDS. Targeting Wnt/β-catenin signaling and this 
communication therefore represents a potential therapeutic strategy to reduce 
acute inflammation in ALI/ARDS patients. 
 
Lastly, we discovered that Axin1, a scaffold protein, was degraded during 
influenza virus infection of mice. More importantly, we found that Axin1 boosted 
type I IFN response to influenza virus infection through the stimulation of JNK/c-
Jun and Smad3 signaling. Axin1 also interacted with IFIT1/2/3, a viral RNA 
sensor complex. In addition, Axin1 specifically promoted the degradation of 
hnRNP M, a nucleoprotein required for efﬁcient activity of influenza virus 
polymerases, and sequentially EZH2. Axin1 and its chemical stabilizer, XAV939, 
successfully reduced influenza virus and respiratory syncytial virus replication, 
and protected the mice from influenza virus infection. Thus, our study provides 
new mechanistic insights into the regulation of type I IFN response and presents a 
new potential therapeutics of targeting Axin1 against influenza virus infection and 
reducing the incidence of viral pneumonia. 
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CHAPTER I 
 
 
INTRODUCTION 
 
1.1 Acute lung injury 
Acute lung injury (ALI) and its severe form, acute respiratory distress syndrome (ARDS), 
are life-threatening diseases caused by a variety of reasons including sepsis, trauma, drug 
overdose, multiple transfusions, and viral or bacterial pneumonia (1). ALI/ARDS is characterized 
by damage the of capillary-alveolar interface, initiation of proinflammatory cytokine and 
chemokine storm, and infiltration of inflammatory cells (2). It is clearly recognized as a syndrome 
of acute respiratory failure and acute inflammation with up to 40% mortality in human patients 
(3). Clinically, ALI/ARDS is defined as acute respiratory distress with severe hypoxemia 
(PaO2/FIO2<300 for ALI, and PaO2/FIO2<200 for ARDS) and diffuse alveolar infiltrates on chest 
X-ray (4).   
The alveolar epithelium plays prominent roles in the pathogenesis of ALI by serving as a 
primary barrier of defense against various insults and regulating immune response (5). It consists 
of two different types of cells: the terminally differentiated squamous alveolar epithelial type I 
cells (AEC I), which covers around 95% of the total lung surface area, and the surfactant 
producing cuboidal alveolar epithelial type II cells (AEC II), which participates in host defense 
(6). AEC I are more sensitive to injury than other lung cells (7). Damage of AEC I is observed in 
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all forms of ALI, leading to the deficiency of gas exchange and disruption of fluid clearance. The 
molecular mechanisms of AEC I death during ALI have been studied to some extent involving 
the regulation of several signaling pathways, such as TGF-β pathway, NFκB pathway, and 
Fas/FasL-mediated pathway (8). It will be significantly beneficial if novel signaling pathways 
regulating AEC I death can be identified.  
The neutrophil is an essential component of the innate immune system and vital to our 
lives. However, inflammatory damage caused by activated neutrophils also contributes to the 
progression of ALI/ARDS (9). Activation and transmigration of neutrophils through endothelium, 
interstitium, and epithelium is the central event in the development of ALI/ARDS. Activated 
neutrophils release cytotoxic compounds (proteolytic enzymes, cationic peptides, and ROS) that 
can injure host cells (10). The depletion of neutrophils is protective in some animal models of 
ALI (11-13). Lung edema and endothelial and epithelial cells injuries accompanied by infiltration 
of neutrophils are broadly accepted as the classic paradigms in this acute lung inflammation 
scenario (14).  
Adhesion molecules such as inter-cellular adhesion molecule 1 (ICAM-1 or CD54) and 
vascular adhesion molecules (VCAM-1 or CD106) are involved in the sequestration, adhesion, 
and subsequent transendothelial/epithelial migration of neutrophils mediated by β2 (CD18/CD11) 
and  α4β1 (CD49d/CD29), α4β7 (CD49d/CD103) integrins during ALI (10). What is not clear is 
the relative contribution of selectins (P, E, and L-selectins) and adhesion molecules (VCAM-1, 
ICAM-1, and JAMs) to the whole infiltration process (capture, rolling, adhesion, and 
transmigration) of inflammatory cells during ALI (9). There is evidence that up-regulation of 
ICAM-1 and VCAM-1 in pulmonary vascular endothelium promotes neutrophil sequestration and 
mediates strong adhesion of neutrophils to endothelial cells (9). ICAM-1 and VCAM-1 are also 
expressed in AEC and mediates the adhesion of neutrophils and macrophages, and facilitates the 
transepithelial migration of monocytes (15-17). Up-regulation of both ICAM-1 and VCAM-1 
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occurs as a result of increased gene transcription in response to inflammatory cytokines such as 
TNF-α and IL-1β (18). The promoter regions of ICAM-1 and VCAM-1 genes contain several 
NFκB (P50/P60) binding sites. Mutation of either of these elements abolishes its cytokine 
responsiveness (18). Considering the critical role of ICAM-1 and VCAM-1 in the progression of 
acute lung inflammation, it is important to perform more detailed studies on the mechanisms 
which control their expression. 
Platelets are the central mediators in hemostasis of circulatory system and also contribute 
to acute pulmonary inflammation by regulating inflammatory response of endothelial cells and 
activation of leukocytes (19-21). There is emerging evidence that acute pulmonary inflammation 
is associated with the activation of aggressive platelets in the blood and sequestration in 
pulmonary vascular beds (22,23). Platelet activation following the onset of thrombocytopenia 
leads to the release of cytokines (IL-1β and CD40L), chemokines (PF4, CCL5 and RANTES), 
and other soluble factors (PFA and Dkk1), and aggregation of platelets with neutrophils or 
monocytes via cell surface P-selectin (CD62P) (22,24,25). Platelets also interact with endothelial 
cells, resulting in the increase of vascular permeability, and promoting the release of 
proinflammatory cytokines (IL-6) or chemokines (IL-8) (26). Blocking of platelet-leukocyte 
interaction (27), platelet depletion (28), and anti-platelets therapy (19,29) have all been proved to 
be protective in the animal model of ALI/ARDS. Platelet components  are found in the 
bronchoalveolar fluid (BAL) in ALI (30). However, it is not clear whether platelets can directly 
affect the functions of alveolar epithelium (22). Novel functions of platelets in regulating 
ALI/ARDS need to be explored. 
1.2 Purinergic P2X7 receptor (P2X7R) and lung diseases 
The purinergic receptor P2X7R, a transmembrane ligand-gated ion channel receptor 
activated by extracellular ATP, is widely expressed in a variety of cells including endothelial 
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cells, epithelial cells, fibroblasts, monocytes, lymphocytes and dendritic cells (31). It shares, in 
common with other P2X receptors, the ability to form nonselective cation channels. On the other 
hand, the unusually long C terminus of P2X7R seems to allow it couple to a spectrum of 
downstream targets responsible for its cytotoxic properties (32).  
Stimulation of P2X7R with low concentrations of ATP opens a membrane channel within 
millisecond, and causes the influx of small cations (Na
+
, Ca
2+, 
and K
+
) (33). However, high 
concentrations of ATP or sustained stimulations lead to membrane blebbing and apoptotic or 
necrotic cell death in P2X7R-expressing cells including epithelial cells, endothelial cells, stem 
cells and macrophages (34-37). Extracellular ATP-induced cell death has been observed in colitis 
(38), spinal cord injury (39), and glomerulonephritis (40). However, the contribution of ATP and 
its receptors to AEC I death during ALI/ARDS is not well understood.  
P2X7R is required for mature IL-1β and IL-18 production and release from immune cells 
because of its essential role in inflammasome-mediated cytokine signaling cascade and caspase 
activation (32,41). In the lung, P2X7R deficient mice have a protective phenotype in LPS-
induced ALI (42) and bleomycin-induced lung fibrosis (43) with attenuated inflammation. 
P2X7R is also involved in the pathogenesis of several other chronic lung inflammatory diseases 
such as asthma and emphysema, in which it functions as an inflammatory mediator (44,45). 
P2X7R has previously been found to be expressed specifically in AEC I and regulating lung 
surfactant secretion in a paracrine manner (46,47). Together with its ability to modulate 
pulmonary inflammatory response, P2X7R could act as a potential regulator of AEC I cell death 
in response to pathological insults. 
1.3 Wnt/β-catenin signaling and lung diseases 
Wnt is a family of secreted glycoproteins and plays an important role in development, 
tissue regeneration, and cell fate determination (48). In the absence of Wnt ligands, the 
 
 
5 
 
intracellular β-catenin is phosphorylated by glycogen synthase kinase-3β (GSK-3β) and degraded 
in proteasome. The binding of Wnt ligands with frizzled receptors leads to the disruption of GSK-
3β-mediated phosphorylation of β-catenin and thus attenuation of proteasome-mediated 
degradation. The stabilized β-catenin then translocates into the nucleus, where it binds to T-cell 
factor (TCF)/Lymphoid enhancer factor (LEF) transcription factor to increase the transcription of 
its downstream genes (49). 
Wnt/β-catenin signaling is instrumental in orchestrating proper lung development in 
embryos (50) and regeneration of lung epithelium after injury in adults (51-54). Activating 
Wnt/β-catenin signaling inhibits apoptosis induced by activating the intrinsic or mitochondrial 
pathway, such as starvation or hydrogen peroxide, or the extracellular or receptor pathway, such 
as TRAIL and TNFα (55). Blocking the Wnt/β-catenin signaling prevents cell proliferation and 
results in apoptosis or necrosis (56,57). In the lung, activation of Wnt/β-catenin signaling 
promotes AEC II survival (52) while depletion of β-catenin in AEC results in an increased AEC 
death in bleomycin-induced lung injury model (58). β-catenin-regulated CCN extracellular 
matrix-associated signaling proteins also promote epithelial repair after inflammatory lung injury 
(59). The direct effect of Wnt/β- signaling in AEC I injury during ALI is unknown. 
In inflammatory lung diseases, depression of Wnt/β-catenin signaling is observed in 
COPD (60,61) and asthma patients (62,63), and contributes to their dysfunctional epithelial 
repair. Wnt/β-catenin signaling is also inhibited in mechanical ventilation (MV)-insulted and S. 
pneumoniae-infected lungs (64,65). On the other hand, up-regulation of Wnt/β-catenin signaling 
has also been demonstrated in resolution of acute lung injury and alveolar epithelium repair 
following acute injury (66,67). Interestingly, transepithelial migration of neutrophils also 
activates Wnt/β-catenin signaling in AEC II and accelerates the process of repair (54). All of 
these studies reveal a dynamic, complicated, and subtle response of Wnt/β-catenin signaling in 
inflammatory lung diseases. Considering a great number of Wnt/β-catenin signaling agonists and 
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antagonists are in the pre-clinical development stage (68), characterizing the role of Wnt/β-
catenin signaling will open a new window to amplify our potential to control these diseases. 
It has been reported that Wnt/β-catenin signaling can inhibit the endothelial and epithelial 
inflammatory response by suppressing proinflammatory cytokines  (62,69), chemokines (70,71), 
adhesion molecule (70,72), and other inflammatory regulators (70,73) potentially through 
interacting with NFκB signaling under different inflammatory conditions (71,73,74). Although 
the importance of Wnt/β-catenin signaling in regulating inflammatory response is emerging, 
limited evidence is available for its implication in acute lung inflammation. Recent studies reveal 
essential roles of Wnt/β-catenin signaling in the pathogenesis of several adult lung diseases 
including pulmonary fibrosis (58,75), asthma (76), and chronic obstructive pulmonary disease 
(COPD) (77,78). Wnt antagonist sFRP1 was recently shown to be largely responsible for the 
inhibition of Wnt/β-catenin signaling in experimental emphysema (79). Considering the reduced 
capacity of BAL from ARDS patients to activate Wnt/β-catenin signaling in fibroblast [118], it is 
particularly important to identify the potential elevation of Wnt antagonists and investigate the 
emerging importance of Wnt/β-catenin signaling in progression of acute lung inflammation. 
Recent evidence also points to important roles of Wnt antagonist Dkk1 in several 
inflammatory conditions such as atherosclerosis, arthritis, and osteoporosis by regulating 
inflammatory response of endothelial cells and homeostasis of epithelial cells (25,80,81). As a 
potential therapeutic target to limit the damage of inflammation, Dkk1 is also developed as a 
serum biomarker of inflammatory diseases and cancer patients (82-84). Neutralization therapy 
targeting Dkk1 has also shed light on osteolytic disease patients (81,85). Interestingly, Dkk1, as 
an important product of activated platelets (25), also accumulates in alveolar epithelium and BAL 
of idiopathic pulmonary fibrosis (IPF), in which Wnt/β-catenin signaling is aberrantly activated 
and modulates cell proliferation (86). However, the role of Dkk1 in development of ALI has not 
been studied.  
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1.4 Influenza virus and Type I IFN response 
The mortality rate of pneumonia and influenza virus infection continually declined 
through the 20
th
 century because of the improvement of anteceded medical strategies for 
prevention of lung infections (87,88). However, acute pulmonary infection remains a substantial 
concern because acute lower respiratory infections still cause the most deaths and are the largest 
economic burden among all infectious diseases worldwide (87-89). Unlike respiratory syncytial 
virus (RSV), which is the major cause of respiratory illness (bronchiolitis or pneumonia) in young 
children (90) and occasionally in adults (118), influenza virus has the ability to span on patients 
of all ages even adults (91). 
The influenza virus belongs to the Orthomyxoviriade family and is classified into three 
types: A, B, and C according to their internal protein sequences (92). In the U.S., up to 20% of 
the population gets the flu each year, resulting in more than 200,000 hospitalizations, 36,000 
deaths, and $87 billion in healthcare costs from seasonal flu-related complications (89). There is a 
risk that new strains of influenza can emerge and spread globally, causing pandemic-scale illness 
(14). The current treatment for influenza virus infection is to use antiviral drugs that target the 
viral proteins (neuraminidase and M2 channel), which only works if no new strains of influenza 
virus emerge (93). However, influenza viral proteins change due to a high mutation rate; As a 
result the virus can become resistant to these drugs. Thus, there is a critical need to develop 
improved anti-influenza medicines that are effective regardless of virus changes. 
Interferon (IFN) was discovered in 1957 as an agent that can inhibit (interfere) the 
replication of influenza virus (94). The IFN family of cytokines is now recognized as the most 
potent vertebrate-derived signals for mobilizing antimicrobial effector functions against 
intracellular pathogens (95). Type I IFN (IFNβ, 12 IFNαs, IFNδ, IFNε, IFNκ, IFNο, and IFNτ), 
best known for their antiviral properties, mediate the induction of both innate immune response 
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and subsequent adaptive immunity to virus infection (96). It is widely accepted that viral 
attachment and viral dsRNA intermediates accumulating during virus replication are the primary 
mediators triggering IFNs production, which ultimately results in expression of thousands of IFN-
stimulated genes (ISGs) (PKR, Mx proteins, OAS1, and etc.) and interrupts virus life cycle (97). 
In the early phase of infection, Toll-like receptors, cytosolic RIG-1-like receptors (RIG-1 
and MDA5), NOD-like receptors and C-type lectin receptors are major viral sensors involved in 
innate recognition of influenza virus (98). Recently, the novel IFN-regulated viral RNA sensor, 
interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) was also implicated in antiviral 
activity (99). Activation of type I IFN expression by these pattern recognition receptors (PRRs) is 
highly controlled by several transcription factors (TFs) including c-Jun/ATF2 (AP1), interferon 
regulatory factor 3/7 (IRF3/7), and p50/p65 (NFκB) (100). In the later phase of infection, secreted 
type I IFN signal stimulates type I IFN receptor (IFNAR1/2) in both autocrine and paracrine 
fashion, and finally turns on cellular antiviral status (101). 
Influenza virus is very effective at taking advantage of host cellular signaling to support 
its viral replication. However, this dependency can also be utilized to develop novel antiviral 
approaches by targeting these host factors (102,103). Genome-wide screening has been utilized to 
identify hundreds of host factors involved in influenza virus replication (104-107). Proteomics 
approaches and yeast two-hybrid analyses have also been used to identify numerous host 
molecules that interact with influenza virus components, especially involvement of non-structural 
protein 1 (NS1)-associated proteins in immune response (108-110) and Wnt/β-catenin signaling 
components (111). These functional genomics and proteomics have provided broad views of host 
response in virus-host interactions. However, they have been less effective in pinpointing the 
specific host factors in antiviral response. 
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Axin, which was identified from analysis of the mouse-Fused locus, is a negative 
regulator of Axis formation in the development of mouse embryos (112). Axin protein is present 
in two isoform (Axin1 and Axin2), and acts as an architectural platform for the degradation of the 
oncogenic protein β-catenin (113,114). Axin1 has, in fact, emerged as a multidomain scaffolding 
protein for many other signaling pathways, including C-Jun-NH2-kinase (JNK) mitogen-activated 
protein kinase (MAPK) signaling, p53 signaling, and transformation growth factor β (TGF-β) 
signaling (115). These intriguing roles of Axin1 in β-catenin-independent manner open the door 
to its function in multiple physiological and pathological processes. In the infectious diseases, 
Axin1 shows a preventive effect on bacterial Salmonella invasiveness and modulates 
inflammatory response during the infection (116). On the other hand, silencing of Axin1 up-
regulates type I human immunodeficiency virus (HIV-1) gene expression and viral replication 
(117). However, there is no report on the involvement of Axin1 in the influenza virus infection 
and type I IFN response. 
1.5 Specific aims and significances 
In spite of the great strides made to understand the pathogenesis of ALI/ARDS, 
unacceptable morbidity and mortality remain, and formidable challenges persist. The treatment 
approach to ALI/ARDS is still relying on ventilatory and cardiovascular support because of the 
limited knowledge about the fundamental mechanisms that initiate and propagate the lung injury. 
Thus, the present study is designed to better understand the molecular mechanism behind AEC I 
injury, acute inflammatory response, and host defense against pathogen invasion during 
development of ALI/ARDS. To this end, we have laid down three specific objectives: 
Specific Aim I: Investigate the roles of P2X7R and Wnt/β-catenin signaling in regulating AEC I 
death during ALI/ARDS 
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Specific Aim II: Explore the function of platelet-derived Wnt antagonist Dkk1 in ICAM-
1/VCAM-1 mediated neutrophilic acute lung inflammation 
Specific Aim III: Study the potential antiviral function of Axin1 as a type I IFN stimulator 
against influenza virus infection 
Significance: A novel functional crosstalk between P2X7R-mediated purinergic signaling and 
Wnt/β-catenin signaling in regulating AEC I injury during ALI/ARDS is identified. Important 
roles of Wnt/β-catenin signaling in mitigating acute inflammatory response, and a Dkk1-mediated 
communication between platelets and AEC during ALI/ARDS are reported for the first time as 
well. Targeting Wnt/β-catenin signaling and this paracrine communication therefore represent a 
potential therapeutic strategy to limit the damage of ALI/ARDS. Our study also provides new 
mechanistic insights into the regulation of type I IFN response and presents a potential new 
broad-spectrum antiviral therapy by targeting Axin1 for the first time. 
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CHAPTER II 
 
 
WNT3A MITIGATES ACUTE LUNG INJURY BY REDUCING P2X7 RECEPTOR-
MEDIATED ALVEOLAR EPITHELIAL TYPE I CELL DEATH 
 
2.1 Abstract 
Acute lung injury (ALI) is characterized by pulmonary endothelial and epithelial cell 
damage, and loss of alveolar-capillary barrier. We have previously shown that P2X7 receptor 
(P2X7R), a cell death receptor, is specifically expressed in alveolar epithelial type I cells (AEC I). 
In this study, we hypothesized that P2X7R-mediated purinergic signaling and its interaction with 
Wnt/β-catenin signaling contributes to AEC I death. We examined the effect of P2X7R agonist 
2’-3’-O-(4-benzoylbenzoyl)-ATP (BzATP) and Wnt agonist Wnt3a on AEC I death in vitro and 
in vivo. We also assessed the therapeutic potential of Wnt3a in a clinically relevant ALI model of 
intratracheal lipopolysaccharide (LPS) exposure in ventilated mice. We found that the activation 
of P2X7R by BzATP caused the death of AEC I by suppressing Wnt/β-catenin signaling through 
stimulating glycogen synthase kinase-3β (GSK-3β) and proteasome. On the other hand, the 
activation of Wnt/β-catenin signaling by Wnt3a, GSK-3β inhibitor, or proteasome inhibitor 
blocked the P2X7R-mediated cell death. More importantly, Wnt3a attenuated the AEC I damage 
caused by intratracheal instillation of BzATP in rats or LPS in ventilated mice. Our results 
suggest that Wnt3a overrides the effect of P2X7R on the Wnt/β-catenin signaling to prevent the 
AEC I death and restrict the severity of ALI. 
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2.2 Introduction 
Acute lung injury (ALI) and its severe form, acute respiratory distress syndrome (ARDS), 
are life-threatening diseases caused by a variety of reasons, including sepsis, trauma, and 
pneumonia (1). The alveolar epithelium consists of alveolar epithelial type I cells (AEC I) and 
alveolar epithelial type II cells (AEC II) and is believed to play an important role in the 
pathogenesis of ALI. AEC I cover most of the alveolar surface area and are the primary barrier of 
defense against the variety of insults (2,3). They are more sensitive to injury in comparison with 
other lung cells. Damage of AEC I can be observed in all types of ALI, leading to the deficiency 
of gas exchange, disruption of fluid clearance, and amplification of acute inflammation. Several 
molecular signaling pathways, such as TGF-β pathway, NFκB pathway, and Fas/FasL-mediated 
pathway, have been reported to regulate AEC I death during ALI (4). 
Wnt is a family of highly conserved secreted signaling molecules and plays an important 
role in embryogenesis, tissue repair, and cell differentiation (5). Without the binding of Wnt 
ligands to the cells, the intracellular β-catenin is phosphorylated by glycogen synthase kinase-3β 
(GSK-3β) and degraded in proteasomes, and thus Wnt/β-catenin signaling is inactive. On the 
other hand, the binding of Wnt ligands with frizzled receptors on the cell surface leads to the 
disruption of GSK-3β-mediated phosphorylation of β-catenin and thus attenuation of its 
proteasome-mediated degradation. The stabilized intracellular β-catenin then translocates into the 
nucleus, where it binds to T-cell factor (TCF)/ Lymphoid enhancer factor (LEF) transcription 
factors to increase the transcription of its downstream genes. 
We have previously shown that pleiotrophin and miR-375 regulate Wnt/β-catenin 
signaling during alveolar epithelial cell differentiation (6,7). Recent studies reveal essential roles 
of Wnt/β-catenin signaling in the pathogenesis of several lung diseases, including pulmonary 
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fibrosis (8,9), asthma (10), and chronic obstructive pulmonary disease (COPD) (11,12). 
Activation of Wnt/β-catenin signaling improves AEC II survival (13) while deletion of β-catenin 
in AEC results in an increased AEC death (8). Interestingly, transepithelial migration of 
neutrophils also activates Wnt/β-catenin signaling in AEC II and accelerates the epithelial repair 
(14). Thus, it is important to explore the potential contribution of Wnt/β-catenin to AEC I damage 
during ALI. 
P2X7R is a transmembrane ligand-gated ion channel receptor activated by extracellular 
ATP (15). We have previously found that P2X7R is specifically expressed in AEC I and regulates 
lung surfactant secretion (16,17). However, high concentrations of ATP or sustained stimulations 
could lead to apoptosis or necrosis in P2X7R-expressing cells (18,19). P2X7R knockout mice 
have shown a protective phenotype in LPS-induced acute lung injury (20). Together with its 
ability to regulate pulmonary inflammatory response (21), P2X7R could act as a potential 
modulator of AEC I cell death in response to pathological insults. 
In this study, we report for the first time the important integration of Wnt/β-catenin 
signaling and P2X7R-mediated purinergic signaling in AEC I death during ALI. The finding 
could be translated into a new therapeutic approach. 
2.3 Materials and Methods 
2.3.1 Cell culture 
E10 cells, a gift from Dr. Mary Williams (Pulmonary Center, Boston University School 
of Medicine, MA, US), were cultured in CMRL 1066 supplemented with glutamax
®
, 
penicillin/streptomycin and 10% heat-inactivated fetal bovine serum (FBS) (Atlantic Biological, 
Miami, FL). R3/1, a gift from Dr. Roland Koslowski, Technische Universität Dresden, Germany, 
was maintained in RPMI 1640 complemented with 10 % FBS and penicillin/streptomycin. HEK 
293 cells (ATCC, Manassas, VA) and HEK293 cells stably expressing rat P2X7R (HEK293-
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P2X7R), a gift from Dr. Annmarie Surprenant (University of Manchester, Manchester, UK) were 
maintained in DMEM supplemented with 10% FBS and 100 µM non-essential amino acids. A549 
cells (ATCC, Manassas, VA) were cultured in RPMI-1640 medium containing 10% FBS. H441 
cells (ATCC, Manassas, VA) were maintained in F-12K Medium complemented with 10 % FBS. 
Cells were grown at 37 °C in a humidified atmosphere containing 5% CO2. 
2.3.2 Primary AEC I-like Cells 
Primary AEC I-like cells were obtained by culturing primary AEC II on plastic plates for 
7 days. To isolate AEC II, rat lung was perfused using solution II (0.9% NaCl, 0.1% glucose, 
30 mM HEPES, 6 mM KCl, 0.1 mg/ml streptomycin sulfate, 0.07 mg/ml penicillin G, 
0.07 mg/ml EGTA, 3 mM Na2HPO4, and 3 mM NaH2PO4, pH 7.4) to clear the red blood cells. 
Then the lung was lavaged with solution I (solution II plus 3 mM MgSO4 and 1.5 mM CaCl2), 
and digested with elastase (3 units/ml) for 3 X 12 min at 37°C. Then, the lung was chopped with 
a Mcllwain tissue chopper, and the cell suspension was digested with 100 ng/ml DNase I and 
filtered through 160- and 37-μm nylon mesh once and 15-μm nylon mesh twice. Then cells were 
seeded on rat IgG-coated polystyrene bacteriological plates twice for 45 min and 30 min to 
remove macrophages. The unattached cells were collected by centrifugation. The isolated AEC II 
had a purity of 90% and a viability of over 98%. To obtain AEC I-like cells, AEC II were seeded 
onto 96-well tissue culture plastic dishes at a density of 1 x 10
6
 cells/plate in MEM with 10% 
FBS. After overnight culture, the culture media was changed to DMEM supplemented with 10% 
FBS. The medium was changed every 48 hours until day 7. 
2.3.3 Preparation of conditioned medium 
Overexpressing soluble murine Wnt3a/Wnt5a cell lines and control murine L cell line 
(ATCC) were maintained in DMEM supplemented with 10% FBS, 1% L-glutamine, and 0.4 
mg/ml G418 (Invitrogen, Carlsbad, CA). To obtain Wnt3a-, Wnt5a- or control (Con)-conditioned 
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medium (CM), cells were cultured in fresh growth medium without G418 for 4 days and changed 
into fresh G418-free medium for additional 3 days. The cultured media were mixed, sterile-
filtered, and stored at -80°C until use. The activity of Wnt3a_CM was determined by a TOPflash 
assay performed in 293T cells. Wnt3a_CM normally showed an approximately 7-fold increase of 
the reporter activity compared to Con_CM. To concentrate the soluble Wnt3a, 20 ml Wnt3a_CM 
was reduced into 2 ml 10X Wnt3a_CM by an ultra-filtration kit (Millipore, Billerica, MA). 
2.3.4 Silencing of P2X7R in E10 cells 
 Two adenovirus-based shRNA vectors, si-P2X7R (1) and si-P2X7R (2), previously 
constructed in our lab were utilized to knockdown P2X7R (17). E10 cells were infected with 
virus control (si-control), si-P2X7R (1) and si-P2X7R (2) for 4 days at a multiplicity of infection 
(MOI) of 100 before BzATP treatment. 
2.3.5 Cell viability and lactate dehydrogenase (LDH) assays 
At the end of BzATP (Sigma-Aldrich, St. Louis, MO) treatment, cell viability was 
assessed by the Cell Viability Assay Kit (Millipore, Billerica, MA) which measured the activity 
of mitochondrial dehydrogenases. Data was normalized to the control without any treatment. The 
release of LDH was measured with a LDH assay kit (Diagnostic Chemicals Inc. CT). The values 
were expressed as a percentage of actual LDH in the medium to the maximal LDH released by 
freeze-thaw insults. 
2.3.6 Western blot 
The cells were lyzed in M-PER Mammalian Protein Extraction Reagent containing 1% 
Halt Protease Inhibitor Cocktail (Pierce, Rockford, IL) at 4°C, followed by sonication and 
freeze/thaw cycles. The proteins were separated in 10% SDS-PAGE and transferred to 
nitrocellulose membranes. The membranes were stained with Ponceau-S to view the transfer 
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quality. Then the membranes were blocked for 1 hour at room temperature with 5% dried milk in 
Tris-buffered saline (10 mM Tris/HCl, 100 mM NaCl and 0.05% Tween; pH 7.5) (TBS-T) and 
incubated overnight at 4°C with anti-P2X7R (1:500, SIGMA, St. Louis, MO), anti-activated β-
catenin (1:1000, Millipore, Billerica, MA), anti-total β-catenin (1:2000, BD Transduction 
Laboratories, San Jose, CA), anti-Bcl2 (1:1000, Santa Cruz Biotechnology, Santa Cruz, CA), 
anti-PCNA (1:2000, Santa Cruz Biotechnology, Santa Cruz, CA), anti-GSK-3β (1:2000, BD 
Transduction Laboratories, San Jose, CA), anti-GSK-3β (pY216) (1:1000, BD Transduction 
Laboratories, San Jose, CA), anti-GSK-3β (pS9) (1:1000, Cell Signaling Technology, Danvers, 
MA),  anti-β-actin (1:2000, SIGMA, St. Louis, MO), and anti-GAPDH (1:400, Santa Cruz 
Biotechnology, Santa Cruz, CA) antibodies. The blots were then rinsed in TBS-T, and incubated 
for 1 hour at room temperature with goat anti-rabbit, or goat anti-mouse secondary antibodies, 
coupled to horseradish peroxidase (1:2000, Jackson Immunoresearch, West Grove, PA). After 
being washed, the blots were developed by SuperSignal West Pico Chemiluminescent Substrate 
(Pierce, Rockford, IL). 
2.3.7 Quantitative real-time PCR 
Total RNA was extracted from cells or tissues using TRI-Reagent (Molecular Research 
Center, Cincinnati, OH) following the manufacturer's instructions. RNA was digested with 
TURBO DNase (Ambion, Austin, TX, USA) to remove the genomic DNA contamination. One 
µg of RNA was reverse-transcribed into cDNA using M-MLV reverse transcriptase (Invitrogen, 
Carlsbad, CA), random primers, and oligo dT (Promega, Madison, WI). Real-time PCR was 
carried out on 7900HT Fast Real-Time PCR System using SYBR Green I detection Master Mix 
(Eurogentec, CA). The primers were designed using Primer Express® software (Applied 
Biosystems, Foster City, CA), and listed in Table II.1. PCR involved an initial denaturation step 
at 94°C for 5 min, followed by 40 cycles of amplification (94°C for 30 s, 60°C for 1 min). A 
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dissociation curve was generated after each PCR to view the specificity of the amplification. All 
of the data was normalized to 18S rRNA. 
Table II.1. PCR primer sequences for mouse genes 
2.3.8 Immunofluorescence 
E10 cells were cultured on 24-well plastic plates. Before collection, the cells were briefly 
washed with PBS and fixed with 4% paraformaldehyde for 15 min. After being washed with 
PBS, the cells were permeabilized with 0.3% Triton X-100 for 10 min and blocked with 10% 
FBS for 1 hour at room temperature. After rinse, the cells were incubated overnight with primary 
antibodies against β-catenin (1:200). Subsequently, cells were washed with PBS and incubated 
with Alexa 568-conjugated goat anti-mouse IgG (Invitrogen, Carlsbad, CA) for 1 hour. The 
nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI, 1:1000, Invitrogen, 
Carlsbad, CA) for 2 min. Images were acquired using a Nikon Eclipse TE-2000 inverted 
fluorescence microscope. 
2.3.9 TOPflash Assay 
E10 cells were seeded in 96-well plastic plates. After reaching 85% confluence, the cells 
were transfected with 1 ng the Renilla luciferase control plasmid phRL-TK (Promega, WI) and 20 
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ng LEF/TCF reporter plasmid TOPflash (Millipore, MA) or FOPflash (a negative control plasmid 
for TOPflash, which has mutated LEF/TCF binding sites) using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA). After 24 hours, cells were treated with 400 µM BzATP for 0 - 12 hours. Dual-
luciferase assay was performed using the Dual-Luciferase
®
 Reporter Assay System (Promega, 
Madison, WI). 
2.3.10 Proteasome activity assay 
 To measure proteasome activity, 100 µg of cell lysate was diluted with assay buffer (50 
mM Tris [pH 7.4], 5 mM MgCl2, 2 mM dithiothreitol, and 2 mM ATP) to a final volume of 1 ml 
and incubated with 50 µM fluorogenic proteasome substrate Suc-LLVY-AMC (AnaSpec, 
Fremont, CA). Proteolytic activities, reflected by the release of the fluorescent group, 7-amido-4-
methylcoumarin (AMC), were continuously monitored in 30 min at 37°C by a fluorescence plate 
reader (Spectramax M2, Molecular Devices, Sunnyvale, CA) with excitation and emission 
wavelengths of 380 and 460 nm, respectively. 
2.3.11 Animals 
Male C57BL/6N mice (6 – 8 weeks old) were purchased from Jackson Laboratory (Bar 
Harbor, ME). Male Sprague-Dawley rats were purchased from Charles River Breeding 
Laboratories (Wilmington, MA). All the animals were housed and cared for by the Laboratory 
Animal Resource Unit, Oklahoma State University. Experimental protocols were reviewed and 
approved by the Institutional Animal Care and Use Committee of Oklahoma State University. 
2.3.12 BzATP-induced acute lung injury in rat 
Male Sprague-Dawley rats (275-300 g) were divided to four groups (n=8/group): 1) 
vehicle (200 µl PBS), 2) BzATP (10 mg/kg b.w. in 200 µl PBS), 3) BzATP and Wnt3a_CM (10 
mg/kg b.w. BzATP in 100 µl PBS and 100 µl 10X Wnt3a_CM), and 4) BzATP and Con_CM (10 
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mg/kg b.w. BzATP in 100 µl PBS and 100 µl 10X Con_CM). Rats were anesthetized with 
intraperitoneal injection of ketamine (40 mg/kg b.w.) and xylazine (8 mg/kg b.w.). All of the 
reagents were intratracheally instilled. 24 hours after intratracheal instillation, a tracheotomy was 
performed. Bronchoalveolar lavage (BAL) was collected by lavaging the right lungs with 10 ml 
of normal saline. After centrifugation at 380 g for 10 min at 4°C, the cell pellets were 
resuspended in 1 ml of normal saline. Cell-free BAL and tissue samples of lavaged right lungs 
were immediately frozen in liquid nitrogen and stored at -80°C for subsequent analysis. 
Unlavaged left lungs were fixed in 4% paraformaldehyde for histological analysis. 
2.3.13 LPS-induced acute lung injury in a ventilated mouse model 
Male C57BL/6N mice (8 weeks) were divided into four groups (n=8/group): 1) 
lipopolysaccharides LPS from Escherichia coli 055:B5 (0.5 mg/kg b.w.) in 20 µl 10X Wnt3a 
conditional medium, 2) LPS 0.5 mg/kg b.w. in 20 µl 10X Con_CM, 3) LPS 0.5 mg/kg b.w. in 20 
µl normal saline, 4) Control, without LPS and mechanical ventilation. LPS was intratracheally 
delivered into the lung. 1 hour after intratracheal instillation, mice were ventilated with a tidal 
volume of 12 ml/kg, a rate of 125 bpm, and 3 cm H2O PEEP for 2.5 hours. At the end of 
ventilation, a tracheotomy was performed. The lungs were lavaged with 1 ml of normal saline 
three times. BAL was collected and centrifuged at 380 g for 10 min at 4°C. BAL cell pellets were 
resuspended in 200 µl of normal saline for subsequent analysis. Cell- free BAL fluid and lavaged 
lung tissue samples were frozen in liquid nitrogen and stored in −80°C freezer. 
2.3.14 BAL analysis 
Protein concentrations in the BAL fluid were determined by a Bio-Rad protein assay 
(Bio-Rad Laboratories, Hercules, CA). The total number of cells in BAL was counted with a 
hemocytometer. Differential cell count was performed on the BAL cells visualized by Wright-
Giemsa staining. LDH activity in the BAL fluid was determined by a Cytotoxicity Detection kit 
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(Roche Applied Sciences, Indianapolis, IN) using type III L-lactic dehydrogenase (SIGMA, St. 
Louis, MO) as standards. 
2.3.15 Western blot for T1α in BAL 
For rat samples, BAL fluid (70 µl) was added with 7 µl SDS sample buffer (62.5 mM 
Tris HCl, pH 6.8, containing 5% 2-mercaptoethanol, 2% SDS, 10% glycerol, and 0.01% 
bromphenol blue) and heated at 95°C until 25 µl volume was reached. A monoclonal anti-T1α 
(1:2000, a gift from Dr. Mary C Williams, Boston University) antibody was used as a primary 
antibody. For mouse samples, BAL fluid (20 µl) was added with 4 µl SDS sample buffer and 
heated at 95 °C for 10 minutes. A hamster anti- T1α (1:2000, 8.1.1, DHSB, Iowa City, IO) was 
used as a primary antibody. Films were developed and scanned. The densities of bands were 
quantified by ImageJ software (National Institutes of Health, Bethesda, Maryland 
[http://rsb.info.nih.gov/ij/]). 
2.3.16 Statistical analysis 
The results were analyzed by one-way ANOVA with posthoc Tukey’s test for multiple 
comparisons of control and treatment groups, or Student’s t-test using GraphPad Prism (version 
6). All results were reported as means ± s.e.m. (n=3-8 for each condition).  
2.4 Results 
2.4.1 P2X7R expression in lung cells 
We have previously shown that P2X7R is specifically expressed in AEC I of the lung 
(16). Here we examined the expression of P2X7R in several lung cell lines by Western blot. 
HEK293-P2X7R cells, stably transfected cell line with P2X7R, were used as a positive control. 
P2X7R expression was observed in E10, an AEC I cell line and MLE15, a lung epithelial cell 
line. However, HEK293 (a human epithelial kidney cell line), R3/1 (a rat AEC I cell lines), A549 
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(a human carcinoma AEC II cell line), Pre-TII (a rat fetal AEC II cell line), H441 (a human lung 
papillary adenocarcinoma epithelial cell line), RLE-6TN (a rat lung AEC II cell line), and RFL-6 
(a fetal lung fibroblast cell line), had no P2X7R expression (Fig. II.1A). The mRNA expression 
of mouse P2X subunits was further analyzed by PCR. P2X3R, P2X4R, P2X6R and P2X7R 
subunits were highly expressed in E10 cells.  The expression of P2X1R and P2X5R subunits were 
barely detectable, and P2X2R had no expression in E10 cells. All of the P2X subunits were 
expressed in the lung tissue (Fig. II. 1B). 
 
Fig. II.1. Expression of P2X receptors in the lung cells. (A) Protein expression of P2X7R in different 
lung cell lines (20 µg total protein) was analyzed by Western blot using β-actin as an internal control. (B) 
mRNA expression of P2XRs in E10 cells and normal mouse lung tissues was determined by 
electrophoresis using real-time PCR product with GAPDH as an loading control. 
2.4.2 Prolonged activation of P2X7R causes cell death 
Because P2X7R is well-known as a cell death receptor, we tested cell viability upon the 
activation of P2X7R in E10 cells. Treatment of E10 cells with BzATP, a potent P2X7R agonist, 
for 12 hours significantly decreased cell viability in a dose-dependent manner as measured by 
MTT assay and counting cell numbers (Fig. II. 2A and B). Direct cell lysis was monitored by 
LDH release. High doses (>200 µM) of BzATP dramatically increased LDH release from dead 
cells (Fig. II. 2C). To determine the specificity of BzATP, oxidized ATP (oATP, a P2X7R 
antagonist) was utilized to block P2X7R activity. Pre-incubation of E10 cells with 500 µM oATP 
totally attenuated the BzATP effect on cell viability (Fig. II. 2D) and LDH release (Fig. II. 2E). 
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Furthermore, silencing of P2X7R also significantly inhibited BzATP-induced reduction of cell 
viability (Fig. II. 3A) and increase of LDH release (Fig. II. 3B). In addition, BzATP did not 
induce cell death in the lung cells, A549 and H441, that do not express P2X7R (Fig. II. 3C and 
D). To determine whether BzATP-mediated cell death is reversible, E10 cells were treated with 
BzATP for various times and allowed them to recover in a normal medium without BzATP for 8 
hours. The cells treated for up to 6 hours were reversible. However, if the cells were treated for 
longer than 8 hours, the cells cannot be recovered (Fig. II. 2F). 
 
Fig. II. 2. Prolonged activation of P2X7R leads to E10 cell death. E10 cells were incubated with 
different concentrations of BzATP for 12 hours. Cell viability (A), viable cell numbers (B), and released 
LDH (C) were measured. E10 cells were treated with 400 µM BzATP in the absence or presence of 500 
µM oATP for 12 hours. Cell viability (D) and released LDH (E) were measured. (F) E10 cells were treated 
with 400 µM BzATP for different times and recovered in a normal medium without BzATP for 6 hours, 
cell viability was determined. Data shown are means ± s.e.m. of three independent experiments, and 
statistical significance was determined by one-way ANOVA analysis with posthoc Tukey’s test.   *P<0.001 
v.s. control without any treatment or 0 time, **P<0.001 v.s. 400 µM BzATP, and #P<0.005 v.s. si-control. 
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Fig. II. 3: Activation of P2X7R causes alveolar epithelial cell death. E10 cells were infected by 
adenovirus-based shRNA vectors (virus control (si-control), si-P2X7R (1) and si-P2X7R (2)) for 4 days 
and then treated with 400 µM BzATP for 12 hours. Cell viability (A) and Released LDH (B) were 
measured. A549 cells (C) and H441 cells (D) were incubated with different concentrations of BzATP for 
12 hours. Cell viability was measured. Data shown are means ± s.e.m. of three independent experiments. 
Statistical significance was determined by one-way ANOVA analysis with posthoc Tukey’s test.  *P<0.001 
v.s. control without any treatment or 0 time, **P<0.001 v.s. 400 µM BzATP, #P<0.005 v.s. si-control. 
2.4.3 Activation of P2X7R suppresses Wnt/β-catenin signaling 
Wnt/β-catenin signaling is important for cell proliferation and survival (5). We 
determined whether P2X7R-mediated cell death is due to down-regulation of the Wnt/β-catenin 
signaling. Several components of Wnt/β-catenin signaling were analyzed after BzATP treatment. 
Western analysis demonstrated that activated β-catenin and, to less extent, total β-catenin were 
down-regulated by BzATP treatment (Fig. II. 4A). Immunostaining confirmed that β-catenin 
level was significantly decreased (Fig. II. 4B). Proliferating cell nuclear antigen (PCNA) and B-
cell lymphoma 2 (Bcl-2), classic cell survival proteins, were reduced as well (Fig. II. 4A). To 
further determine the effect of BzATP on β-catenin/TCF/LEF activity, dual-luciferase assay was 
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used to determine the activity of TOPflash, a TCF/LEF reporter plasmid expressing firefly 
luciferase. BzATP significantly decreased TOPflash activity (Fig. II. 4C). However, BzATP had 
no effect on FOPflash, a plasmid containing a mutated TCF/LEF binding site (Fig. II. 4C). 
Furthermore, we examined the mRNA expression of several Wnt/β-catenin downstream genes: 
Bmp4, Axin2, Cyclin D1, and Cyclin E1. Real-time PCR showed that expressions of all these 
four target genes were inhibited (Fig. II. 4D and E). Our results indicate that Wnt/β-catenin 
signaling is suppressed by BzATP treatment. 
 
Fig. II. 4.  Activation of P2X7R represses Wnt/β-catenin signaling. (A) E10 cells were treated with 400 
µM BzATP for 0, 0.5, 2, 4, 8, and 12 hours with or without 50% Wnt3a_CM. Western blot was carried out 
to determine the protein expression of activated β-catenin, total β-catenin, Bcl-2, and PCNA. The 
expression of β-actin was used as an internal control. (B) Immunostaining was used to assess the β-catenin  
protein Expression in E10 cells  treated with or without 400 µM BzATP for 6 hours. (C) Two hundred ng 
TOPflash/FOPflash and 1 ng pRL-TK, a control plasmid expressing a Renilla luciferase, were transfected 
into E10 cells. Two days after transfection, E10 cells were treated with 400 µM BzATP for 4 hours with or 
without 50% Wnt3a_CM. Dual-luciferase assay was performed and the results were expressed as the ratio 
of TOPflash/FOPflash luciferase activity to pRL-TK. (D) E10 cells were stimulated with 400 µM BzATP 
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for 8 hours with or without 50% Wnt3a_CM. The relative mRNA expression of Axin2 (fold changes) was 
determined using Real-time PCR and normalized to 18S rRNA. (E) The relative mRNA expression of 
Wnt/β-catenin downstream genes in E10 cells treated with 400 µM BzATP  for various times were 
determined using Real-time PCR.Data. shown are means ± s.e.m. of three independent experiments.  
Statistical significance was determined by ANOVA analysis with posthoc Tukey’s test. *P<0.001 v.s. 
control. **P<0.001 v.s. BzATP without Wnt3a_CM. 
2.4.4 Wnt3a blocks P2X7R-mediated cell death 
To evaluate the role of Wnt/β-catenin signaling in P2X7R-mediated cell death, we 
activated Wnt/β-catenin signaling with its nature ligand, Wnt3a and examined its effect on 
P2X7R-mediated depression of Wnt/β-catenin signaling and cell death. Wnt3a_CM and 
Wnt5a_CM were obtained from L-cells stably expressed Wnt3a or Wnt5a. The medium from L-
cells (Con_CM) were used as a control. The pre-treatment of E10 cells with Wnt3a_CM 
prevented BzATP-mediated down-regulation of total β-catenin and activated β-catenin (Fig. II. 
4A), inhibition of TOPflash activity (Fig. II. 4C) and decrease of Axin2 (Fig. II. 4D). As shown 
above, BzATP treatment caused a decrease in cell number of E10 cells. Wnt3a_CM, but not 
Wnt5a_CM or Con_CM prevented the BzATP-induced decrease in cell number (Fig. II. 7A). 
Immunstaining confirmed the activation of Wnt/β-catenin in E10 cells by Wnt3a as evidenced by 
nuclear translocation of β-catenin (Fig. II. 5A). Activation of Wnt/β-catenin signaling by 
Wnt3a_CM in E10 cells also blocked P2X7-mediated decrease in cell viability and increase in 
LDH release (Fig. II. 5B and C). Wnt3a_CM also protected primary AEC-I like cells from 
BzATP-induced cell death (Fig. II. 5D). YO-PRO dye uptake triggered by BzATP was not 
inhibited by Wnt3a_CM (Fig. II. 6), indicating that P2X7R activity itself is not affected by the 
activation of Wnt/β-catenin signaling. 
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Fig. II. 5. Wnt3a blocks P2X7R-mediated cell death. E10 cells were treated with 400 µM BzATP for 8 
hours together with 50% Control (Con), Wnt3a or Wnt5a conditioned medium (CM). (A) Immunostaining 
was carried out to determine β-catenin localization. (Scale bar: 50 µm). (B, C) Cell viability and LDH 
release were measured. Data shown are means ± s.e.m. Statistical significance was determined by ANOVA 
analysis with posthoc Tukey’s test. *P< 0.001 v.s. control. **P<0.001 v.s. Con_CM. n=3. (D) Primary AEC 
I-like cells were treated with 0 - 500 µM BzATP for 12 hours with 50% Control (Con) or Wnt3a_CM, and 
Cell viability was measured.  
 
 
Fig. II. 6. Effect of Wnt3a on P2X7R activity. E10 cells were treated with 400 µM BzATP for 15 min 
and incubated with YO-PRO dye for 10 min. The fluorescence was observed using a Nikon TE-2000 
inverted microscope. 
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2.4.5 Activation of P2X7R stimulates GSK-3β and proteasome activities 
Since Wnt3a is known to inhibit GSK-3β, resulting in the activation of Wnt/ β-catenin 
signaling (5), we examined whether the down-regulation of Wnt/β-catenin pathway by P2X7R is 
through the stimulation of GSK-3β. We monitored the phosphorylation of Y216, an activated 
form of GSK-3β, and the phosphorylation of S9, an inactivated form of GSK-3β. The activation 
of P2X7R by BzATP increased the phosphorylation of Y216 and decreased the phosphorylation 
of S9 in GSK-3β without affecting the total GSK-3β expression (Fig. II. 7A). The result indicates 
that BzATP stimulates GSK-3β activity. As expected, LiCl, a selective inhibitor of GSK-3β, 
activated Wnt/β-catenin signaling as indicated by the translocation of β-catenin into nucleus (Fig. 
II. 7B) and reduced BzATP-mediated cell death (Fig. II. 7C and D).  
 
Fig. II. 7: GSK-3β mediates P2X7R-induced cell death. (A) E10 cells were incubated with 400 μM 
BzATP for different periods of time. The level of Tyr-216 (pY216) and Ser-9 (pS9) phosphorylated GSK-
3β and total GSK-3β were determined by Western blot. (B) E10 cells were treated with 10, 25, and 50 mM 
LiCl in the presence or absence of 400 µM BzATP for 8 hours, and then immuo-stained with anti-β-catenin 
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antibodies. Scale bar: 50 µm. (C, D) E10 cells were treated with 400 uM BzATP together with different 
concentrations of LiCl for 8 hours. Cell viability and released LDH were measured. Data shown are means 
± s.e.m. of three independent experiments. Statistical significance was deterined by ANOVA analysis with 
posthoc Tukey’s test. *P<0.01 v.s. control (no BzATP). **P<0.01 v.s. BzATP only.  
 
Fig. II. 8. Proteasome is involved in P2X7R-mediated cell death. (A) E10 cells were treated with 400 
μM BzATP for 6 hours. Cell lysate was incubated with Suc-LLVY-AMC. Fluorescence was measured 
every 5 min for 30 min. The amount of AMC liberated per unit time was calculated as relative proteasome 
activity. (B, C) E10 cells were treated with 400 µM BzATP with or without 500 µM MG-132 for 8 hours. 
Cell viability and released LDH were measured. Values represent means ± s.e.m. of three independent 
experiments. Statistical significance was determined by ANOVA analysis with posthoc Tukey’s test. 
*P<0.001 v.s. Control. **P<0.001 v.s. BzATP alone. 
Because phosphorylated β-catenin by GSK-3β can be degraded through ubiquitin-
proteasome system (5), we determined whether BzATP affected proteasome activity. The 
treatment of E10 cells with BzATP increased proteasome activity by one fold (Fig. II. 8A). 
Furthermore, MG-132, a proteasome inhibitor, blocked BzATP-mediated reduction of cell 
viability and increase in LDH release (Fig. II. 8B and C). 
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2.4.6 Wnt3a reduces AEC I death in BzATP-induced ALI in rats 
To further investigate the role of P2X7R in AEC I death, BzATP was intratracheally 
instilled into the lung of rats. Histological examination of lung tissues showed evidence of diffuse 
lung injury with significant alveolar septal necrosis and edema formation seen in BzATP-treated 
mice (Fig. II. 9A). Bronchoalveolar lavage (BAL) cell analysis indicated that activation of 
P2X7R led to a 3.2-fold increase of alveolar macrophages. However, no significant neutrophil 
infiltrations were observed (Fig. II. 9B). BAL protein level was elevated by BzATP (Fig. II. 9C). 
LDH activity in BAL, representing necrotic cell death, was also increased by BzATP treatment 
(Fig. II. 9D). An increase of T1α, an AEC I marker, was observed in BAL of the BzATP-treated 
group, indicating AEC I damage (Fig. II. 9E).  Instillation of Wnt3a_CM together with BzATP 
dramatically reduced the number of alveolar macrophages in BAL and BAL protein concentration 
in comparison with Con_CM (Fig. II. 9B and C). Wnt3a also significantly decreased LDH and 
T1α release caused by BzATP (Fig. II. 9D and E). It was noted that both protein concentration 
and LDH activity in BAL were higher in Con_CM than PBS group. This is likely due to existence 
of proteins and LDH in the conditioned medium. These results indicated that Wnt3a can limit 
AEC I death induced by activation of P2X7R in rats. 
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Fig. II. 9. Wnt3a reduces AEC I death in BzATP-treated rats. The rats were intratracheally instilled 
with BzATP with control (Con) or Wnt3a conditioned medium (CM) for 24 hours. (A) Histological 
analysis. Parafin sections (4 µm) of the lungs were stained with H&E. Control (a), BzATP (b), 
BzATP+Wnt3a_CM (c), and BzATP+Con_CM (d). Scale bar: 100 µm. (B) Total cell number and 
differential cell count in BAL. (C) BAL protein concentration. (D) LDH activity in BAL. (E) T1α protein 
in BAL. Representative bands of Western blots were shown. Values represent means ± s.e.m. (n=8/group). 
Statistical significance was determined by one-way ANOVA analysis with posthoc Tukey’s test. *P<0.01 
v.s. PBS alone group. **P<0.01 v.s. BzATP + Con_CM group. 
2.4.7 Wnt3a reduces AEC I death during LPS-induced ALI in a ventilated mouse model 
Because bacterial infection and mechanical ventilation are two major causes of 
ALI/ARDS in clinical situations, we further took use of a two-hit mouse model of ALI (22), 
which account for the impacts of both factors: LPS as bacterial infection and noninjurious 
mechanical ventilation (MV) as clinical mechanical ventilation support. In comparison with the 
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Con_CM group, Wnt3a_CM dramatically reduced the protein concentration in BAL fluid (Fig. II. 
10A). LDH activity in BAL was also decreased 40% in Wnt3a_CM-treated group (Fig. II. 10B). 
Most importantly, T1α in BAL was 70% less in Wnt3a_CM -treated group than the control group 
(Fig. II. 10C). These results indicated that the activation of canonical Wnt/β-catenin signaling can 
significantly reduce AEC I death during ALI. 
Fig. II. 10. Wnt3a reduces AEC I death in LPS and mechanical ventilation (LM)-induced ALI in 
mice. The mice were intratracheally instilled with LPS (0.5 mg/kg) for 1 hour and then ventilated for 2.5 
hours (12 ml/kg, a respiratory rate of 125 bpm, and 3 cm H2O PEEP).  (A) Protein concentration in BAL. 
(B) LDH activity in BAL. (C) T1α protein in BAL. Values represent means ± s.e.m. (n=8/group). Statistical 
significance was determined by Student’s t-test. *P<0.01 v.s. LM + Con_CM group.  
2.5 Discussion 
In this study, we investigated the mechanisms of P2X7R-mediated AEC I death during 
ALI. We found that the activation of P2X7R caused AEC I death at least partly by depressing the 
Wnt/β-catenin signaling pathway via GSK-3β and proteasome. The activation of the Wnt/β-
catenin signaling or inhibition of GSK-3β or proteasome prevented P2X7R-mediated AEC I 
death. Furthermore, Wnt3a significantly reduced the AEC I damage caused by intratracheal 
instillation of BzATP in rats and LPS exposure in a ventilated mouse model. 
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ATP-induced cell death has been observed in P2X7R-expressing cells and can be blocked 
by P2X7R inhibitors (18,19). We have previously shown that P2X7R is highly expressed in AEC 
I in the lung (16). This gives us an idea that P2X7R might mediate AEC I death. This is supported 
by our current data showing that the treatment of E10 with BzATP, a specific P2X7R agonist, 
decreased cell viability in a dose-dependent manner, which was blocked by oATP, a P2X7R 
antagonist.  
Activating Wnt/β-catenin signaling inhibits apoptosis induced by activating the intrinsic 
or mitochondrial pathway, such as starvation or hydrogen peroxide (23), or  the extracellular or 
receptor pathway, such as TRAIL and TNF-α (23). Blocking the Wnt/β-catenin pathway prevents 
cell proliferation and results in apoptosis or necrosis (24). BzATP-induced AEC I death is likely 
through down-regulating Wnt/β-catenin signaling pathway since we observed BzATP activated 
GSK-3β and proteasome activity, and decreased β-catenin protein level. 
 The high level of extracellular ATP could be one major contributor to the pathogenesis of 
ALI (25). ATP-induced cell death has been observed in several inflammatory diseases, including 
colitis (26), spinal cord injury (27)  and glomerulonephritis (28). P2X7R knockout mice have a 
protective phenotype of attenuated inflammation in models of LPS -induced acute lung injury 
(20) and bleomycin-induced lung fibrosis (25). P2X7R also functions as an inflammatory 
mediator and participates in the pathogenesis of several chronic lung inflammatory diseases such 
as asthma and emphysema (29). In our study, direct activation of P2X7R through intratracheal 
instillation of BzATP caused severe AEC I death and LDH release into the alveolar space, 
supporting the contribution of P2X7R to the pathogenesis of ALI.  
There are no standard methods for activating Wnt/β-catenin signaling in the lung, an 
organ with more than 40 different types of cells. Wnt3a is one of the reported ligands 
constitutively present in the lung that can activate Wnt/β-catenin signaling in alveolar epithelium 
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(9). We demonstrated that the activation of Wnt/β-catenin in the lungs by Wnt3a reduced AEC I 
damage in two rodent models: BzATP-induced ALI in rat and a clinically relevant LPS and 
mechanical ventilation model in mice. GSK3β inhibitors are other compounds that are used to 
activate Wnt/β-catenin signaling in mice. These inhibitors attenuate the acute inflammation in 
blemocycin- and carrageenan-induced ALI (30). However, they also interfere with other signaling 
including NFκB and NFAT. Our current findings provide proof-of-concept to manipulate Wnt/β-
catenin signaling as an efficient way to limit AEC I death during ALI. 
Taken together, we demonstrate that P2X7R induces AEC I death by suppressing Wnt/β-
catenin signaling via activating GSK-3β and proteasome. Wnt3a overcomes P2X7R-mediated 
down-regulation of Wnt/β-catenin signaling and prevents AEC I death during the acute phase of 
ALI/ARDS (Fig. II. 11). Our study on Wnt/β-catenin signaling and P2X7R-mediated purinergic 
signaling provides insights for future drug development and new therapeutic strategies of 
exploration. 
 
Fig. II. 11. A model of P2X7R-induced AEC I death and Wnt3a–mediated protection. Activation of 
P2X7R by ATP activates GSK-3β and proteasome and leads to degradation of β-catenin. This causes AEC 
I cell death. With the addition of Wnt3a, the activity of GSK-3β is inhibited. β-catenin is accumulated in 
the cytoplasmic and translocated into cell nucleus, which enhances AEC I cell survival. 
 
 
41 
 
2.6 Acknowledgements 
We thank Dr. Mary Williams (Boston University) for providing anti-T1α antibody and 
E10 cells with the permission of Dr. Al Malkinson (University of Colorado), Dr. Annmarie 
Surprenant (University of Manchester) for HEK293-P2X7R cells, Dr. Roland Koslowski 
(Dresden University of Technology) for R3/1 cells, Dr. Joseph Alcorn (University of Texas 
Health Sciences Center at Houston) for MLE-15 cells, Dr. Rama Mallamaplli (University of 
Pittsburgh) for Pre-TII cells.  Hamster anti-mouse T1α antibody developed by Dr. Andrew Farr 
(University of Washington) was obtained from the Developmental Studies Hybridoma Bank 
developed under the auspices of the NICHD and maintained by The University of Iowa, 
Department of Biology, Iowa City, IA 52242.  
2.7 Reference 
 1.  Matthay, M. A. and Zemans, R. L. (2011) Annu. Rev. Pathol. 6, 147-163 
 2.  Dobbs, L. G., Johnson, M. D., Vanderbilt, J., Allen, L., and Gonzalez, R. (2010) Cell 
Physiol Biochem. 25, 55-62 
 3.  Chen, J., Chen, Z., Chintagari, N. R., Bhaskaran, M., Jin, N., Narasaraju, T., and Liu, L. 
(2006) J Physiol 572, 625-638 
 4.  Tang, P. S., Mura, M., Seth, R., and Liu, M. (2008) Am J Physiol Lung Cell Mol Physiol 
294, L632-L641 
 5.  Clevers, H. and Nusse, R. (2012) Cell 149, 1192-1205 
 6.  Weng, T., Gao, L., Bhaskaran, M., Guo, Y., Gou, D., Narayanaperumal, J., Chintagari, N. 
R., Zhang, K., and Liu, L. (2009) J. Biol. Chem. 284, 28021-28032 
 7.  Wang, Y., Huang, C., Reddy, C. N., Bhaskaran, M., Weng, T., Guo, Y., Xiao, X., and Liu, 
L. (2013) Nucleic Acids Res. 41, 3833-3844 
 8.  Tanjore, H., Degryse, A. L., Crossno, P. F., Xu, X. C., McConaha, M. E., Jones, B. R., 
Polosukhin, V. V., Bryant, A. J., Cheng, D. S., Newcomb, D. C., McMahon, F. B., Gleaves, 
L. A., Blackwell, T. S., and Lawson, W. E. (2013) Am. J Respir. Crit Care Med. 187, 630-
639 
 9.  Konigshoff, M., Kramer, M., Balsara, N., Wilhelm, J., Amarie, O. V., Jahn, A., Rose, F., 
Fink, L., Seeger, W., Schaefer, L., Gunther, A., and Eickelberg, O. (2009) J. Clin. Invest 
119, 772-787 
 
 
42 
 
 10.  Sharma, S., Tantisira, K., Carey, V., Murphy, A. J., Lasky-Su, J., Celedon, J. C., Lazarus, 
R., Klanderman, B., Rogers, A., Soto-Quiros, M., Avila, L., Mariani, T., Gaedigk, R., 
Leeder, S., Torday, J., Warburton, D., Raby, B., and Weiss, S. T. (2009) Am. J. Respir. Crit 
Care Med. 181, 328-336 
 11.  Kneidinger, N., Yildirim, A. O., Callegari, J., Takenaka, S., Stein, M. M., Dumitrascu, R., 
Bohla, A., Bracke, K. R., Morty, R. E., Brusselle, G. G., Schermuly, R. T., Eickelberg, O., 
and Konigshoff, M. (2011) Am. J Respir. Crit Care Med. 183, 723-733 
 12.  Wang, R., Ahmed, J., Wang, G., Hassan, I., Strulovici-Barel, Y., Hackett, N. R., and 
Crystal, R. G. (2011) PLoS. ONE. 6, e14793 
 13.  Flozak, A. S., Lam, A. P., Russell, S., Jain, M., Peled, O. N., Sheppard, K. A., Beri, R., 
Mutlu, G. M., Budinger, G. S., and Gottardi, C. J. (2009) J. Biol. Chem. 285, 3157-3167 
 14.  Zemans, R. L., Briones, N., Campbell, M., McClendon, J., Young, S. K., Suzuki, T., Yang, 
I. V., De, L. S., Reynolds, S. D., Mason, R. J., Kahn, M., Henson, P. M., Colgan, S. P., and 
Downey, G. P. (2011) Proc. Natl. Acad. Sci. U. S. A 108, 15990-15995 
 15.  Khakh, B. S. and North, R. A. (2006) Nature. 442, 527-532 
 16.  Chen, Z., Jin, N., Narasaraju, T., Chen, J., McFarland, L. R., Scott, M., and Liu, L. (2004) 
Biochem. Biophys. Res. Commun. 319, 774-780 
 17.  Mishra, A., Chintagari, N. R., Guo, Y., Weng, T., Su, L., and Liu, L. (2011) J. Cell Sci. 
124, 657-668 
 18.  Hanley, P. J., Kronlage, M., Kirschning, C., del, R. A., Di, V. F., Leipziger, J., Chessell, I. 
P., Sargin, S., Filippov, M. A., Lindemann, O., Mohr, S., Konigs, V., Schillers, H., Bahler, 
M., and Schwab, A. (2012) J Biol. Chem. 287, 10650-10663 
 19.  Jun, D. J., Kim, J., Jung, S. Y., Song, R., Noh, J. H., Park, Y. S., Ryu, S. H., Kim, J. H., 
Kong, Y. Y., Chung, J. M., and Kim, K. T. (2007) J Biol. Chem. 282, 37350-37358 
 20.  Moncao-Ribeiro, L. C., Cagido, V. R., Lima-Murad, G., Santana, P. T., Riva, D. R., 
Borojevic, R., Zin, W. A., Cavalcante, M. C., Rica, I., Brando-Lima, A. C., Takiya, C. M., 
Faffe, D. S., and Coutinho-Silva, R. (2011) Respir. Physiol Neurobiol. 179, 314-325 
 21.  Ferrari, D., Pizzirani, C., Adinolfi, E., Lemoli, R. M., Curti, A., Idzko, M., Panther, E., and 
Di Virgilio, F. (2006) J. Immunol. 176, 3877-3883 
 22.  Altemeier, W. A., Matute-Bello, G., Frevert, C. W., Kawata, Y., Kajikawa, O., Martin, T. 
R., and Glenny, R. W. (2004) Am. J. Physiol Lung Cell Mol. Physiol 287, L533-L542 
 23.  Doubravska, L., Simova, S., Cermak, L., Valenta, T., Korinek, V., and Andera, L. (2008) 
Apoptosis. 13, 573-587 
 24.  You, L., He, B., Xu, Z., Uematsu, K., Mazieres, J., Fujii, N., Mikami, I., Reguart, N., 
McIntosh, J. K., Kashani-Sabet, M., McCormick, F., and Jablons, D. M. (2004) Cancer Res 
64, 5385-5389 
 
 
43 
 
 25.  Riteau, N., Gasse, P., Fauconnier, L., Gombault, A., Couegnat, M., Fick, L., Kanellopoulos, 
J., Quesniaux, V. F., Marchand-Adam, S., Crestani, B., Ryffel, B., and Couillin, I. (2010) 
Am. J. Respir. Crit Care Med. 182, 774-783 
 26.  Gulbransen, B. D., Bashashati, M., Hirota, S. A., Gui, X., Roberts, J. A., MacDonald, J. A., 
Muruve, D. A., McKay, D. M., Beck, P. L., Mawe, G. M., Thompson, R. J., and Sharkey, 
K. A. (2012) Nat. Med. 18, 600-604 
 27.  Wang, X., Arcuino, G., Takano, T., Lin, J., Peng, W. G., Wan, P., Li, P., Xu, Q., Liu, Q. S., 
Goldman, S. A., and Nedergaard, M. (2004) Nat. Med. 10, 821-827 
 28.  Taylor, S. R., Turner, C. M., Elliott, J. I., McDaid, J., Hewitt, R., Smith, J., Pickering, M. 
C., Whitehouse, D. L., Cook, H. T., Burnstock, G., Pusey, C. D., Unwin, R. J., and Tam, F. 
W. (2009) J Am Soc. Nephrol. 20, 1275-1281 
 29.  Lucattelli, M., Cicko, S., Muller, T., Lommatzsch, M., de, C. G., Cardini, S., Sundas, W., 
Grimm, M., Zeiser, R., Durk, T., Zissel, G., Sorichter, S., Ferrari, D., Di, V. F., Virchow, J. 
C., Lungarella, G., and Idzko, M. (2011) Am. J. Respir. Cell Mol. Biol. 44, 423-429 
 30.  Cuzzocrea, S., Crisafulli, C., Mazzon, E., Esposito, E., Muia, C., Abdelrahman, M., Di, P. 
R., and Thiemermann, C. (2006) Br. J Pharmacol. 149, 687-702 
 
 
 
 
44 
 
CHAPTER III 
 
 
PLATELET-DERIVED WNT ANTAGONIST DICKKOPF-1 IS IMPLICATED IN ICAM-
1/VCAM-1-MEDIATED NEUTROPHILIC ACUTE PULMONARY INFLAMMATION 
 
3.1 Abstract 
Neutrophil infiltration represents the early acute inflammatory response in acute lung 
injury. The recruitment of neutrophils from peripheral blood across endothelial/epithelial barrier 
into alveolar airspace is highly regulated by the adhesion molecules on alveolar epithelial cells 
(AEC). Wnt/β-catenin signaling is involved in the progression of inflammatory lung diseases 
including asthma, emphysema and pulmonary fibrosis. However, the function of Wnt/β-catenin 
signaling in acute lung inflammation is unknown. Here, we identified platelet-derived Dickkopf-1 
(Dkk1) as the major Wnt antagonist contributing to the suppression of Wnt/β-catenin signaling in 
AEC during acute lung inflammation. Intratracheal administration of Wnt3a or neutralization of 
Dkk1 inhibited neutrophil influx into alveolar airspace of injured lungs. Activation of Wnt/β-
catenin signaling in AEC attenuated ICAM-1/VCAM-1-mediated adhesion of both macrophages 
and neutrophils to AEC. We reported for the first time a role of Wnt/β-catenin signaling in 
modulating inflammatory response, and a functional communication between platelets and AEC 
during acute lung inflammation. Targeting Wnt/β-catenin signaling and the communication 
between platelets and AEC therefore represents a potential therapeutic strategy to limit acute 
pulmonary inflammation.
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3.2 Introduction 
Activation and transmigration of neutrophils through endothelium, interstitium, and 
epithelium is the central event in the pathogenesis of ALI/ARDS (1). Activated neutrophils 
release cytotoxic compounds, including proteolytic enzymes, cationic peptides, and ROS, that can 
damage host cells. The depletion of neutrophils has been proven to be protective in multiple 
animal models of ALI (2-4). Adhesion molecules such as inter-cellular adhesion molecule 1 
(ICAM-1 or CD54) and vascular adhesion molecular 1 (VCAM-1 or CD106) are extensively 
involved in the transendothelial/epithelial migration of neutrophils during ALI (1,5). Up-
regulation of ICAM-1 and VCAM-1 expression in pulmonary vascular endothelium promotes 
neutrophil sequestration and mediates strong adhesion of neutrophils to endothelial cells (1). Both 
ICAM-1 and VCAM-1 are also expressed in AEC and mediates the adhesion of neutrophils and 
macrophages, and facilitates the transepithelial migration of monocytes (6-9). Shedding of 
sICAM-1 into alveolar airspace from AEC I is also reported in ALI (10). sICAM-1 is capable of 
activating alveolar macrophages, which play critical roles in host defense and is the major source 
of proinflammatory cytokines including tumor necrosis factor-alpha (TNF-α) and Interleukin-6 
(IL-6) (11). Up-regulation of ICAM-1 and VCAM-1 is generally considered as a result of 
increased gene transcription upon stimulation by inflammatory cytokines such as TNF-α and 
interleukin-1β (IL-1β) (12). The promoter regions of ICAM-1 and VCAM-1 genes have been 
reported to contain several NFκB (P50/P65) binding sites. Mutations of these sites eliminate their 
responsiveness to TNFα (12). 
Platelets are the central mediators in hemostasis of circulatory system and the major 
contributors to acute pulmonary inflammation by regulating inflammatory response of endothelial 
cells and activation of leukocytes (13-16). Acute pulmonary inflammation is always associated 
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with the activation of aggressive platelets in the blood and sequestration in pulmonary vascular 
beds (17,18). Platelet production following the onset thrombocytopenia are increased by up to 20-
fold under the conditions
 
of peripheral demand and inflammation (18). Activated platelets release 
cytokines (IL-1β and CD40L), chemokines (PF4, CCL5 and RANTES), and other soluble factors 
(PFA and Dkk1) to amplify the acute inflammatory response. Platelets also aggregate with 
neutrophils or monocytes via cell surface P-selectin (CD62P), which is considered as a molecular 
marker of platelet activation, and provides supportive juxtacrine and paracrine signals (18-20). By 
interacting with endothelial cells, activated platelets cause increases of vascular permeability, and 
promote the release of proinflammatory cytokines (IL-6) or chemokines (IL-8) from endothelial 
cells as well (19,21) . Platelet components are found in the broncheoalveolar fluid (BAL) from 
ARDS patients (22). However, it is still unclear whether platelets directly affect the functions of 
alveolar epithelium during the development of ALI (18). 
Wnt/β-catenin signaling is essential in maintaining proper embryonic lung development 
(23) and adult lung repair after injury (24-27). Although the importance of Wnt/β-catenin 
signaling in regulating inflammation is emerging, only limited evidence is available for its 
implication in acute pulmonary inflammation (28-31). Wnt/β-catenin signaling inhibits the acute 
inflammatory response by suppressing proinflammatory cytokines (TNFα and IL-6) (31,32), 
chemokines (IL-8 and CCL2) (33,34), adhesion molecule (VCAM-1 and ICAM-1) (34,35), and 
other inflammatory mediators (NOS2, TC1, and COX-2) (34,36) through interacting with NFκB 
signaling and TLR-mediated signaling (33,36,37). In inflammatory lung diseases, suppression of 
Wnt/β-catenin signaling can be observed in COPD (38) and asthma patients (32,39), and 
contributes to the dysfunctional epithelial repair.  Inhibition of Wnt/β-catenin signaling is also 
reported in mechanical ventilation (MV)-insulted and S. pneumoniae-infected lungs (40,41). 
Elevation of Wnt antagonist sFRP1 in experimental emphysema is recently discovered to be 
substantially responsible for the depression of Wnt/β-catenin signaling (42). Taken with the 
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reduced capacity of BAL from ARDS patients to activate Wnt/β-catenin signaling in fibroblasts 
(106), it is important to identify the potential deposition of Wnt antagonists in the alveolar space 
and explore the emerging roles of Wnt/β-catenin signaling in the pathogenesis of ALI/ARDS. 
By regulating inflammatory response of endothelial cells and homeostasis of epithelial 
cells, Wnt antagonist Dkk1 contributes to several inflammatory diseases such as atherosclerosis, 
arthritis, and osteoporosis (19,28,43). In idiopathic pulmonary fibrosis (IPF) patients, Dkk1, 
potentially released from activated platelets, is found to accumulate in alveolar space and BAL 
(44). 
In the current study, we utilized a clinically relevant two-hit acute lung inflammation 
model induced by low tidal volume MV and moderate dose of LPS (45), and identified platelet-
derived Dkk1 as a major Wnt antagonist accompanied with suppression of Wnt/β-catenin 
signaling in AEC. The same phenomenon was further confirmed in murine models of bacterial or 
influenza viral pneumonia. The administration of Wnt3a or neutralization of Dkk1 significantly 
reduced ICAM-1/VCAM-1-mediated neutrophil trafficking during acute lung inflammation. By 
targeting their promoters, Wnt/β-catenin signaling negatively regulated ICAM-1 and VCAM-1 
expression in AEC. Our results indicated a novel function of Wnt/β-catenin signaling in AEC 
and a distinctive communication between platelets and alveolar epithelium. We thus conclude 
that platelet-derived Wnt antagonist Dkk1 plays an important role in the control of Wnt/β-catenin 
signaling to regulate ICAM-1/VCAM-1-mediated acute inflammatory response, and the 
pharmacological interferences of platelet function, Dkk1 production, or Wnt/β-catenin signaling 
may constitute new therapeutic methods to restrict the pathogenesis of acute pulmonary 
inflammation. 
3.3 Materials and methods 
3.3.1 Animals 
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Male C57BL/6N mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA). 
Male Sprague-Dawley rats were purchased from Charles River Breeding Laboratories 
(Wilmington, MA). All the animals were housed and cared for by OSU Laboratory Animal 
Resource Unit (LARU) operated by the Center for Veterinary Health Sciences (Stillwater, OK). 
All animal experimental procedures were reviewed and approved by the Institutional Animal 
Care Committee (IACUC) of Oklahoma State University.  
3.3.2 Cell culture 
The AEC I cell line, E10 cell was a generous gift from M. Williams (Pulmonary Center, 
Boston University School of Medicine, MA) and was cultured in CMRL-1066 medium 
(Invitrogen, CA) containing 10% heat-inactivated fetal bovine serum (FBS) (Atlantic Biological, 
Miami, FL) and 2.5 mM L glutamax
® 
(Invitrogen, CA). Cells were maintained at 37 °C in a 
humidified atmosphere containing 5% CO2.  
3.3.3 Mouse AEC II and AEC isolation and culture 
AEC II (>90%) or AEC I-enriched preparation (33% AEC I and 66% AEC II) from Male 
C57BL/6N mice (6-8 weeks of age) were isolated as described previously (46). Lungs were 
cleared of blood by perfusion with solution II (0.9% NaCl, 0.1% glucose, 10 mM HEPES, pH 
7.4, 5 mM KCl, , 1.7 mM CaCl2, 1.3 mM MgSO4, 3 mM Na2HPO4, 3 mM NaH2PO4, 0.1 mg/ml 
streptomycin sulfate, and 0.06 mg/ml penicillin G). AEC II was released from the lungs by 
intratracheally instilled elastase three times (8 caseinolytic units/ml final concentration in 3 ml 
solution II, Worthington Biomedical, Freehold, NJ) for 20 min each at 37
o
C. Then the lungs were 
chopped and further incubated with DNase I (100 µg/ml, Sigma-Aldrich, St. Louis, MO) for 45 
mins at 37
o
C with gentle agitation. The resulting cell suspension was filtered sequentially through 
160-, 37- and 15-µm nylon filters and centrifuged for 10 mins at 250 x g at 4C. The cell pellet 
was resuspended in DMEM (GIBCO, Grand Island, NY) and incubated in a 100-mm petri dish 
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coated with mouse IgG (75 µg/dish) for 1 hour. The nonadherent cells were centrifuged again and 
resuspended in DMEM containing 10% FBS. Cell viability was determined by trypan blue 
exclusion. AEC II was then seed in 12-well tissue culture plates (Corning) at 1 x 10
6 
cells/well in 
DMEM supplemented with 10% FBS, penicillin, and streptomycin. AEC II was cultured for four 
to five days to allow them trans-differentiate into AEC I-like cells. For AEC I-enriched 
preparation, lungs were cleared of blood as described above and filled with an enzyme mix (3 ml) 
consisting of dispase (250 units/ml, BD Biosciences, Franklin Lakes, NJ) and elastase (4 
units/ml), and incubated at 37C for 15 mins for two runs. After being chopped, lung tissues were 
further digested with the addition of DNase I (100 μg/ml) for 45 mins at 37°C, with intermittent 
shaking. The digested lungs were filtered sequentially through 160-, 37- and 15-µm nylon filters 
and centrifuged for 10 mins at 250 x g at 4 C. Cells were then resuspended in DMEM containing 
10% FBS. Cytospins with either purified AECII or AECI cell-enriched preparations were 
subsequently carried out with 2 x10
5
 cells/slide and the cells were subjected to 
immunofluorescence. 
3.3.4 Rat AEC II isolation 
Rat AEC II were isolated from male Sprague-Dawley rats (180-200 g) as previously 
described in our lab (47). The lungs were perfused using solution I (0.9% NaCl, 0.1% glucose, 30 
mM HEPES, 6 mM KCl, 0.1 mg/ml streptomycin sulfate, 0.07 mg/ml penicillin G, 0.07 mg/ml 
EGTA, 3 mM Na2HPO4, and 3 mM NaH2PO4, at pH 7.4) to clear red blood cells. Then the 
lungs were lavaged with solution II (solution I plus 3 mM MgSO4 and 1.5 mM CaCl2), and 
digested with elastase (3 units/ml) for 3 X 12 mins at 37°C, and chopped with a Mcllwain tissue 
chopper. The cell suspension was further digested with 100 ng/ml DNase I and filtered through 
160- and 37-μm nylon mesh once and 15-μm nylon mesh twice. Then cells were seeded on rat 
IgG-coated polystyrene bacteriological plates twice for 45 and 30 mins to remove macrophages. 
The unattached cells were collected by centrifugation. The isolated AEC II had a purity of 90% 
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and a viability of over 98%. The AEC II were seeded onto 12-well tissue culture plastic plates at 
a density of 1 x 10
6
 cells/plate in DMEM with 10% FBS.  
3.3.5 Preparation of conditional medium 
Murine L-Wnt3a cell line (ATCC, Manassas, VA) producing soluble recombinant mouse 
Wnt3a and control murine L cell line (ATCC, Manassas, VA)  were cultured in DMEM 
containing 10% FBS, 1% L-glutamine, and 0.4 mg/ml G418 (Invitrogen, Carlsbad, CA). To 
generate Wnt3a or control (Con)-conditional medium (CM), cells were cultured in G418-free 
growth medium for 4 days and changed into fresh G418-free medium for additional 3 days. The 
cultured media were mixed, sterile-filtered, aliquoted, and stored at -80°C until use. The activity 
of Wnt3a_CM was determined by TOPflash assay performed in E10 cells. Wnt3a_CM normally 
showed an approximately 6-fold increase of the reporter activity compared with Con_CM. To 
concentrate the soluble Wnt3a, 20 ml Wnt3a_CM or Con_CM were reduced into 2 ml 10X 
Wnt3a_CM or 10X Con_CM by an ultra-filtration kit (Millipore, Billerica, MA). 
3.3.6 Murine acute pulmonary inflammation model induced by LPS and mechanical ventilation 
A two-hit acute lung injury model with a moderate dose of LPS, followed by low tidal 
volume mechanical ventilation was adopted as described before
 
(45). Male C57BL/6N mice (6-8 
weeks of age) were divided into six groups (n=8/group): 1) spontaneous breathing non-ventilated 
control (Blank), 2) LPS in PBS with mechanical ventilation (LM), 3) LPS in Control conditional 
medium with mechanical ventilation (LM+Con_CM), 4) LPS in Wnt3a conditional medium with 
mechanical ventilation (LM+Wnt3a_CM), 5) LPS and mouse IgG2b in PBS with mechanical 
ventilation (LM+Control IgG), and  6) LPS and anti-Dkk1 antibody in PBS with mechanical 
ventilation (LM+Anti-Dkk1). Mice were anesthetized with ketamine (80 mg/kg) and xylazine (10 
mg/kg) intraperitoneally, and half dose 2 hours later. Tracheotomy was performed to expose the 
trachea. Mice were intratracheally instilled with LPS (Escherichia coli serotype 0111:B4, Sigma-
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Aldrich; 0.5 µg/g bodyweight, 1.5 µl/g) or 10X conditional medium (1µl/g). Sixty minutes later, 
mice were ventilated on a small animal ventilator (SAR-830/AP; CWE Inc) with following 
settings: respiratory rate = 125 breaths per minute; inspiratory and expiratory ratio = 1:2; tidal 
volume (Vt) = 12 ml/kg bodyweight; PEEP = 3 cm of H2O and an inspired oxygen fraction of 
0.21 for 150 mins. In Dkk1 neutralization experiments, LPS was co-administered intratracheally 
into the lungs with functional blocking mAb against mouse Dkk1 (86 µg/mouse, purified mouse 
anti-human Dkk1, MAB1096, R&D Systems. Inc, Minneapolis, MN) and isotype–matched 
control (purified mouse IgG1 isotype control, R&D Systems, Inc). Mechanical ventilation with 
the same settings was started after 60 mins and continued for additional 150 mins as described 
above. At the end of protocol, blood was collected by cardiac puncture. 
3.3.7 Murine model of bacterial pneumonia 
Male C57BL/6N mice (6-8 weeks) were anesthetized intraperitoneally with ketamine (80 
mg/kg body weight) and xylazine (10 mg/kg body weight). After intranasal inoculation of E.coli 
(Strain 19138 from ATCC, 700,000 CFU/mouse), mice were housed for 24 hours and monitored 
every 8 hours. At the end of protocol, mice were sacrificed and blood collected by cardiac 
puncture. 
3.3.8 Murine model of influenza viral pneumonia 
Male C57BL/6N mice (6-8 weeks of age) were anesthetized with intraperitoneal injection 
of ketamine (80 mg/kg body weight) and xylazine (10 mg/kg body weight), and inoculated 
intranasally with H1N1 influenza virus A/Puerto Rico/8/1934 (250 pfu/mouse, ATCC). Mice 
were continually monitored for clinical signs such as ruffled fur and respiratory distress every 12 
hours. Animals were sacrificed on days 0 - 7 post infection and blood collected by cardiac 
puncture.  
3.3.9 Rat model of hyperoxia-induced acute lung injury 
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The hyperoxia model was used previously in our laboratory (47). Male Sprague-Dawley 
rats (180-220 g) were exposed to >95% oxygen in a sealed Plexiglas chamber for 48, 60 or 72 
hours. The CO2 in the chamber was removed by soda lime (Sigma-Aldrich). The control rats were 
exposed to room air. The oxygen concentration was continuously monitored using an oxygen 
sensor (OxyCheq, Marianna, Florida) and the flow rate was maintained at 8 L/min using a flow 
meter. Rats had free access to food and water.  At the end of experiment, rats were sacrificed by 
abdominal arterial puncture. 
3.3.10 Bronchoalveolar lavage analysis 
The mouse lungs were lavaged with 1 ml of normal saline three times. Bronchoalveolar 
lavage (BAL) fluid was collected and centrifuged at 380 x g for 10 mins at 4°C. BAL cell pellets 
were resuspended in 200 μl of normal saline for subsequent analysis. Cell- free BAL fluid and 
lavaged lung tissue samples were frozen in liquid nitrogen and stored in a −80°C freezer. Total 
cell numbers were counted with a standard hemocytometer. Immune cell differential count was 
performed on the air dried cytospin slides visualized by Wright-Giemsa staining (Sigma-Aldrich). 
The total protein concentration in BAL was determined by BCA protein assay kit (Pierce, 
Rockford, IL).  
3.3.11 Lung tissue myeloperoxidase (MPO) activity assay 
Whole lung tissues were homogenized in 1 ml homogenization buffer (50 mM potassium 
phosphate, pH 6.0) by a dounce homogenizer and centrifuged at 14,000 g for 15 mins at 4°C. The 
pellet was resuspended in 1 ml homogenization buffer containing 50 mM 
hexadecyltrimethylammonium bromide (HTAB, Sigma-Aldrich). The samples were sonicated on 
ice for 20 seconds, freeze-thawed twice and centrifuged at 14,000 x g for 10 mins at 4°C. 2.9 ml 
of the homogenization buffer containing 0.167 mg/ml O-danisidine dihydrochloride (Sigma-
Aldrich) and 0.0005% hydrogen peroxide (Sigma-Aldrich) was added to 100 µl of samples and 
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absorbance at 460 nm was measured for 20 mins at 2-min intervals. MPO activities were 
expressed as absorbance per min per milligrams of total protein. 
3.3.12 ELISA 
Dkk1, sVCAM-1, IL-6, and TNFα in BAL or plasma were determined by ELISA 
according to the manufacturers’ instructions (Quantikine mouse sVCAM-1 and Dkk1 
immunoassay; R&D Systems, Minneapolis, MN; and mouse IL-6, TNFα ELISA Ready-SET-Go; 
eBiosciences, San Diego, CA). 
3.3.13 Platelet isolation and stimulation 
Murine platelets were isolated from C57BL/6N mice (6-8 weeks of age) as described 
previously with some modifications (19). Blood was collected into 3.8% sodium citrate (pH 7.4) 
(2:1, volume) by cardiac puncture, and centrifuged at 250 x g for 10 mins to obtain the platelet-
rich plasma (PRP). For platelet stimulation, PRP was treated by 100 μM thrombin receptor 
activating peptide (SFLLRN, Sigma-Aldrich) for indicated times and then centrifuged at 657 x g 
for 7 mins. The supernatant was collected as plasma and the platelet pellet was collected as well. 
For platelet releasate (PR) collection, PRP was centrifuged at 657 x g for 7 mins to pellet the 
platelets. Platelets were then resuspended in Tyrodes-HEPES buffer and stimulated by 0.1 U/ml 
thrombin (Sigma-Aldrich) for  90 mins. PR was collected by centrifugation at 2500 x g for 10 
mins at 4°C. 
3.3.14 Cell-based Dkk1 binding assay 
The binding of Dkk1 to cultured mouse AEC was assayed using an ELISA protocol 
modified from a previous report (9). Freshly isolated mouse AEC II was cultured on fibronectin-
coated 96-well plate until 100% confluence. Recombinant mouse Dkk1 (R&D Systems, 
Minneapolis, MN) was added into wells at different doses for 12 hours. Cells were fixed, washed 
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with PBS containing 0.05% Tween-20, and incubated with anti-mouse Dkk1 (1:200, Abcam, San 
Francisco, CA) mouse monoclonal antibody for 2 hours at room temperature. After being washed 
again, the cells were incubated with HRP-conjugated goat anti-mouse IgG for 1 hour. The cells 
were washed again and a TMB (Tetramethylbenzidine) substrate solution (Invitrogen, Carlsbad, 
CA) was added into the wells and color developed in 30 mins. The intensity of the color was then 
measured at 450 nm. 
3.3.15 Western blot 
The cells and whole lung tissues were homogenized and lysed in M-PER Mammalian 
Protein Extraction Reagent containing 1% Halt Protease/Phosphatase Inhibitor Cocktail (Pierce, 
Rockford, IL) at 4°C, followed by freeze/thaw cycles. The proteins were separated in 8-12% 
SDS-PAGE gels and transferred to nitrocellulose membranes. Then the membranes were blocked 
with 5% dried milk in Tris-buffered saline (10 mM Tris/HCl, 100 mM NaCl and 0.05% Tween; 
pH 7.5) (TBS-T) for 1 hour at room temperature and incubated overnight at 4°C with anti-Dkk1 
(1:500, ab61275, Abcam, San Francisco, CA), anti-activated β-catenin (1:1000, Millipore, 
Billerica, MA), anti-β-catenin (1:2000, BD Transduction Laboratories, San Jose, CA), anti-
VCAM-1 (1:1000, Santa Cruz Biotechnology, Santa Cruz, CA), anti-ICAM-1 (1:500, Abcam, 
San Francisco, CA), anti-CD41 (1:1000, BD Transduction Laboratories, San Jose, CA), anti-
CD141 (1:1000, BD Transduction Laboratories, San Jose, CA), anti-T1α (1:200, 8.1.1, DHSB, 
Iowa City, IO), anti-p-P65 (ser536) (1:1000, Cell Signaling Technology, Danvers, MA), anti-P65 
(1:1000, Cell Signaling Technology, Danvers, MA) and anti-β-actin (1:2000, BD Transduction 
Laboratories) antibodies. The blots were then rinsed in TBS-T, and incubated for 1 hour at room 
temperature with horseradish peroxidase (HRP) labled goat anti-rabbit, goat anti-mouse, or goat-
anti-hamster secondary antibodies (1:2000, Jackson Immunoresearch, West Grove, PA). After 
wash, the blot was developed by SuperSignal West Pico Chemiluminescent Substrate (Pierce, 
Rockford, IL).  
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3.3.16 RNA isolation and Real-time PCR 
Table III.1. Real time-PCR primer sequences 
 
Total RNA was extracted from cultured cells and whole lung tissues using TRI-Reagent 
(Molecular Research Center, Cincinnati, OH). Obtained RNA was digested with TURBO DNase 
(Ambion, Austin, TX, USA) to remove the genomic DNA contamination and quantified by 
Nanodrop (Wilmington, DE). 1 µg RNA were reverse-transcribed into cDNA using M-MLV 
reverse transcriptase (Invitrogen, Carlsbad, CA), random primers, and oligo dT (Promega, 
Madison, WI). Real-time PCRs were performed on 7900HT Fast Real-Time PCR System 
(Applied Biosystem, Foster City, CA) using SYBR Green I (Eurogentec, CA). The primers were 
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designed using Primer Express® (Applied Biosystems, Foster City, CA), and listed in Table III.1. 
PCRs were consisted of an initial denaturation step at 94°C for 5 min, followed by 40 cycles of 
amplification (94°C for 30 s, 60°C for 1min). A dissociation curve was generated after each PCR 
to view the specificity of the amplification. The data was normalized to mouse 18S rRNA.   
3.3.17 Immunohistochemistry  
Immunohistochemistry in lung tissue was performed as described as before
 
(48). Briefly, 
4 µm tissue sections were stained by the sequential use of a monoclonal mouse anti-Dkk1 
antibody (1:50, Abcam, San Francisco, CA) and a biotin-conjugated goat anti-mouse IgG 
antibody (Jackson Immunoresearch, Newmarket, UK). The reaction was visualized using ABC 
reagent (Vector Labs, CA), followed by incubation with TSATM-plus horseradish peroxidase 
system (Vector Labs, CA). Tissue sections were counterstained with hematoxylin and viewed 
under a Nikon Eclipse E600 microscope. The pictures were captured by Photometrics CoolSnap 
CCD camera (Roper Scientific) and processed by Metavue software (Universal Imaging Co.). 
3.3.18 Dual-luciferase assay 
For promoter activity, E10 cells were seeded in 96-well plastic plates. After reaching 
~85% confluence, the cells were transfected with 100 ng/well pGL3_phVCAM-1, 
pGL3_phICAM-1 (Switchgear Genomics, Menlo Park, CA) or pGL3 (Promega, Madison, WI) 
along with 2 ng/well phRL-TK (Promega, Madison, WI) with or without P65_pcDNA3.0 
(Addgene, Cambridge, MA) for indicated time using lipofectamine 2000 (Invitrogen, Carlsbad, 
CA). For NFκB signaling activity, E10 cells were transfected with 100 ng/well pNFκB_luc 
(NFκB response element, Promega, Madison, WI) plasmid along with 2 ng/well phRL-TK 
(Promega, Madison, WI) with or without P65_pcDNA3.0 (Addgene, Cambridge, MA) for 
indicated times. For TOP/FOPFLASH assay, E10 cells were transfected with 100 ng/well 
TOPflash or FOPflash (Millipore, MA) along with 2 ng/well phRL-TK (Promega, Madison, WI) 
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for indicated times. At the end of experiment, cells were lysed in passive cell lysis buffer 
(Promega, Madison, WI). Dual-luciferase assay was performed using the Dual-Luciferase
®
 
Reporter Assay System (Promega, Madison, WI). 
3.3.19 Flow Cytometry 
Fluorescence activated cell sorter (FACS) analysis of freshly isolated platelets was 
performed to quantify the activity of platelets by detecting the surface expression of P-Selectin 
(CD62P) according to a previous report
 
(49). Briefly, platelet-rich plasma was collected from 
mice, fixed in 1% paraformaldehyde for 10 mins, and suspended in FACS buffer (BD 
Biosciences). Then 1 x 10
8
 cells were staining with PE-CD62P (eBioscience, San Diego, CA) and 
FITC-CD41 (platelet marker, eBioscience, San Diego, CA) antibodies or compatible IgGs (mouse 
IgG1κ for CD62P and rat IgG1κ for CD41) for 30 mins in room temperature. FACS analysis 
(Accuri
TM
 C67; BD Biosciences) was performed to identify the percentage of PE-CD62P positive 
cells in FITC-CD41 positive populations. 
3.3.20 Isolation rat neutrophils and alveolar macrophages 
Neutrophils were isolated from Sprague-Dawley rats (200-250 g) by Histopaque 
1119/1077 (Sigma-Aldrich , St. Louis, MO) gradients method as described before (50). Briefly, 5 
ml of freshly collected rat blood (anticoagulated by sodium citrate, 4% w/v Solution) was put on 
the top of the gradient mixture (2.5 ml of Histopaque 1077 and 2.5 ml of Histopaque 1119). This 
mixture was centrifuged at 400 x g for 30 minutes. The second ring (from top to bottom) was 
collected and incubated with RBC Lysis Buffer (BD Biosciences, Franklin Lakes, NJ) to remove 
the erythrocytes. Finally, the cells were washed with HBSS (Hank's Balanced Salt Solution) at 
pH 7.2 at 270 x g for 8 min and resuspended in DMEM containing 10% FBS. Alveolar 
macrophages (AMϕ) were isolated from Sprague-Dawley rats (200-250 g) by bronchoalveolar 
lavage. Rats were lavaged with 7 ml sterile PBS containing 2 mM EDTA (pH 7.2) until a BAL 
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volume of 100 ml was recovered (approximately 18 times). AMϕ was washed twice in PBS and 
resuspended in DMEM containing 10% FBS. 
3.3.21 Cell adhesion assay 
E10 cells were plated into 12-well plate, grown to 90% confluence, treated as indicated in 
the results section and incubated with rat anti-mouse ICAM-1(10 µg/ml, clone YN1/1.7.4, R&D 
System) or rat anti-mouse VCAM-1 (10 µg/ml, M/K-2.7, R&D System). Freshly isolated rat 
AMϕ or neutrophils were added onto E10 cells monolayer and incubated for 30 mins. 
Nonadherent cells were removed by washing each well four times with culture medium very 
carefully. The remaining cells were fixed in 4% paraformaldehyde and visualized by Wright-
Giemsa staining (Sigma-Aldrich, St. Louis, MO). The attached AMϕ and neutrophils were 
counted. 
3.3.22 Immunofluorescence 
Cells were fixed in 4% formaldehyde for 15 mins, followed by incubation in 0.3% Triton 
X-100 for 10 mins. After being blocked in 10% FBS for 30 mins, the cells were then incubated 
with anti-SP-C (1:200, Santa Cruz Biotechnology, Santa Cruz, CA), anti-T1α (1:50, 8.1.1, DHSB, 
Iowa City, IA), anti-β-catenin (1:200, BD Transduction Laboratories, San Jose, CA), or anti-P65 
(1:200, Cell Signaling Technology, Danvers, MA) antibodies at 4 °C overnight. The cells were 
rinsed with PBS and then incubated with Alexa 488-conjugated anti-mouse or anti-hamster 
antibodies (1:250) for 1 h followed by DAPI nuclear staining. Finally, cells were washed and 
viewed by a Nikon Eclipse TE2000-U inverted fluorescence microscope. 
3.3.23 Statistical analysis 
All data were given as mean ± s.e.m. For analysis of statistical differences, one-way 
ANOVA with post hoc Tukey’s test for multiple comparisons, two-tailed Wilcoxon ranked test 
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for non-parametric comparisons, or Student’s t-test for two sets of data were applied. Significance 
was assumed when p values were < 0.05. 
3.4 Results 
3.4.1 Inhibition of Wnt/β-catenin signaling comes together with deposition of Dkk1 in the lungs 
during acute pulmonary inflammation. 
Wnt/β-catenin signaling is involved in several different inflammatory lung diseases by 
regulating
 
cell survival, repair and fibroproliferation (25,38,51). To determine whether Wnt/β-
catenin signaling is modulated during acute lung inflammation, we quantified the mRNAs 
expression of the major components (downstream genes and Wnt ligands) of Wnt/β-catenin 
signaling in whole lung homogenates and freshly isolated AEC from the lungs challenged with 
LPS and mechanical ventilation (LM). As depicted in Fig. III. 1A, mRNA expression of 
downstream genes (Axin2, β-Catenin, Bmp4, and CCND1) was all significantly depressed in both 
injured lungs and AEC.  The mRNA levels of canonical Wnt ligands (Wnt1, Wnt3a, Wnt7b, and 
Wnt11) were also remarkably reduced in LM-challenged lungs and AEC compared to control 
except that Wnt7b was slightly increased in injured lungs. The protein level of the central 
signaling transducer β-catenin and its activated form were both significantly decreased in LM-
challenged lungs (Fig. III. 1B).  
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Fig. III. 1. Wnt/β-catenin signaling is inhibited during LPS and mechanical ventilation induced acute 
pulmonary inflammation. Mice were treated with LPS and mechanical ventilation (LM). Non-ventilated 
mice were used as a control.  (A) The mRNA levels of Wnt signaling components in whole lungs and fresh 
isolated alveolar epithelia cells (AEC) of LM animals were analyzed by Real-time PCR and plotted as 
ratios over the control animals with 18S rRNA as a reference gene. (B) The protein levels of activated β-
catenin and total β-catenin in whole lungs of Control and LM animals with β-actin as an internal control. 
Density of bands was quantified by ImageJ and normalized to control mice. Data are expressed as means ± 
s.e.m. (n=5 animals) and statistical significance determined by Student’s t-test. *p < 0.05 v.s. Control.  
In another murine model of influenza viral pneumonia, mRNAs of downstream genes 
(Axin2, β-Catenin, and Bmp4) and canonical Wnt ligand (Wnt3a) were also dramatically 
inhibited (Fig. III. 2A). Activated form of β-catenin (ABC) was reduced during acute viral 
infection (Fig. III. 2C). However, mRNA expression of other canonical Wnt ligands (Wnt1, 
Wnt7b, and Wnt11) (Fig. III. 2B) and protein expression of β-catenin (Fig. III. 2C) were not 
decreased in influenza viral pneumonia. Similarly, the down-regulation of Wnt target genes, Wnt 
ligands and β-catenin protein was also observed in hyperoxia-induced acute lung injury (Fig. III. 
3).  
 
Fig. III. 2. Wnt/β-catenin signaling is depressed during H1N1 influenza virus-mediated acute 
pulmonary inflammation. Mice were intranasally inoculated with H1N1 influenza A/PR/8/34 virus (250 
pfu) and housed for 1 to 7 days. (n=3/group). The mRNA levels of Wnt signaling components (A) and Wnt 
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ligands (B) in whole lung tissue were measured by Real-time PCR and normalized to control animals 
(without infection) using 18S rRNA as a reference gene. (C) The protein levels of activated β-catenin 
(ABC), total β-catenin, and Dkk1 in whole lung tissue of infected animals using β-actin as an internal 
control. Density of ABC bands was quantified by ImageJ, normalized to control mice, and labeled on the 
top.  Data are shown as means ± s.e.m. (n=3 animals). 
 
Fig. III. 3. Wnt/β-catenin signaling is down-regulated in hyperoxia-associated acute lung injury. The 
rats were exposed to 95% oxygen for 0, 48, 60 or 72 hours. (A) The protein level of β-catenin was 
determined by Western blot using β-actin as an internal control. The mRNA levels of Wnt target genes (B) 
and Wnt ligands (C) were analyzed by Real-time PCR using rat 18S rRNA as reference and normalized to 
control rat. The results are means ± s.e.m. (n = 4 rats). 
To identify the Wnt antagonist that is potentially responsible for this down-regulation, we 
screened mRNA expression of several Wnt antagonists (sFRP1 and Dkk1-4) in LM-challenged 
lungs and found that only Dkk1 was increased (Fig. III. 4A). Dkk1 protein was also up-regulated 
by LM (Fig. III. 4B). Furthermore, mRNA and protein expression of Dkk1 were  greatly induced 
in influenza virus-infected lungs (Fig. III. 4C and G). Interestingly, Dkk1, which was reported to 
accumulate in the lungs of IPF patients (44), was also significantly deposited in alveoli of both 
the LM-challenged and influenza virus-infected lungs (Fig. III. 4F). However, Dkk1 mRNA in 
freshly isolated AEC (data not shown) and Dkk1 protein in BAL of the LM-challenged and 
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influenza virus-infected lungs (Fig. III. 4D and E) were almost undetectable. Instead, Dkk1 in 
plasma from both injured animals were remarkably increased compared with control animals 
(Fig. III. 4D and E). Based on more detailed BAL analyses, profound infusion of Dkk1 into BAL 
during acute viral infection came after endothelial cells damage and disruption of alveolar-
vascular barrier (Fig. III. 4E and G). This indicated that Dkk1 deposited in alveoli was originated 
from the circulating system. Our results also implied a potential paracrine regulatory mechanism 
of Dkk1 on Wnt/β-catenin signaling in AEC during acute pulmonary inflammation. 
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Fig. III. 4. Dkk1 is accumulated in the lung during acute pulmonary inflammation. (A) The mRNA 
expression of Wnt antagonists (sFRP1 and Dkk1-4) in whole lungs of LM-challenged and control mice was 
determined by Real-time PCR and plotted as ratios over control animals with 18S rRNA as a reference. (B) 
The protein level of Dkk1 in whole lung of control and LM-challenged animals was measured by Western 
blot using β-actin as a loading control. Density of bands was quantified by ImageJ and normalized to β-
actin. Result was expressed as a ratio to control animal. (C) The mRNA level of Dkk1 in whole lung tissue 
of H1N1 influenza virus PR/8-infected mice for 0 to 7 days was analyzed by Real-time PCR and 
normalized to control mice with 18S rRNA as a reference. (D) Dkk1 concentrations in BAL and plasma of 
mice following LM challenge (D) and H1N1 influenza virus PR/8 infection (E) were measured by ELISA. 
(F) Immunostaining of Dkk1 in the lungs of Control, LM-challenged, and H1N1 influenza virus PR/8-
infected (7 dpi) mice. Scale bar = 75 µm. (G) The protein levels of T1α (AEC I marker), CD141 
(endothelial cells marker), IgM (epithelial-endothelial barrier damage marker), and Dkk1 in BAL of H1N1 
influenza virus PR/8-infected mice (0-7 dpi) were determined by Western blot. Data are expressed as 
means ± s.e.m. (n=3-8 animals) and statistical significance determined by Student’s t-test. *p < 0.05 v.s. 
Control. 
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3.4.2 Dkk1 is released from activated platelets and binds to AEC during acute pulmonary 
inflammation-associated thrombocytopenia 
Platelets were recently identified as the major source of Dkk1 in the circulation system 
(19). Platelets were also activated in the development of acute pulmonary inflammation and other 
inflammatory diseases (13,18,52). Thus, we first measured the number of circulating platelets in 
LM-challenged, live bacteria-infected, and influenza virus-infected animals. As we expected, 
there was a rapid and transient reduction in the number of circulating platelets, which reflects the 
clinical condition of thrombocytopenia, in animal models of influenza pneumonia (Fig. III. 5A). 
In other two animal models of acute lung inflammation, the numbers of circulating platelets were 
also dramatically decreased (Fig. III. 5B). Although the number of platelets was the lowest at 2 
dpi, platelet activity was increased at the same time point as shown by the increased surface 
expression of CD62P, the marker of platelet activation (18-20) (Fig. III. 5C). Surprisingly, Dkk1 
protein expression was strongly elevated in the isolated platelets from all three animal models 
(Fig. III. 5D-F). Dkk1 was very fast released from activated platelets upon stimulation of 
thrombin receptor by SFLLRN (Fig. III. 6A and B). To determine potential paracrine regulation 
of Dkk1 from platelets on the Wnt/β-catenin signaling in AEC, we measured the binding affinity 
of Dkk1 to AEC and found that the affinity was significantly increased upon TNFα/IL-1β 
stimulation (Fig. III. 6C). This increase was likely due to specific Dkk1 receptor Kermen-
1(KRM1) and co-receptor for Wnt ligands (LRP5 and LRP6) since these receptors were up-
regulated by TNFα/IL-1β treatment as well (Fig. III. 6D). The binding of Dkk1 to AEC depressed 
Wnt/β-catenin signaling (Fig. III. 7) as we expected. Our results here showed that Dkk1 released 
from platelets can be utilized to manipulate Wnt/β-catenin signaling in AEC.  
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Fig. III. 5. Dkk1 protein is induced in activated platelets during acute pulmonary inflammation-
associated thrombocytopenia. (A, B) Circulating platelets count in H1N1 influenza virus PR/8-infected, 
LM-challenged, and live bacteria E.coli-infected mice. (C) Platelets were isolated from the H1N1 influenza 
virus PR/8-infected mice (2 dpi) and labeled with PE-CD62P and FITC-CD41 (1 μg/ml of each). Surface 
expression of CD62P (activation marker) were detected by FACS. (D-F) Protein levels of Dkk1 and CD41 
(platelets marker) in circulating platelets of LM-challenged, live bacteria E.coli-infected, and PR/8-infected 
mice were measured by Western blot with β-actin as a loading control. Data are expressed as means ± 
s.e.m. (n = 3-8 mice) and tested for statistical significance by Student’s t-test. *p < 0.01 v.s. control mice. 
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Fig. III. 6. Dkk1 is released from activated platelets and binds to AEC during acute pulmonary 
inflammation. Platelet-rich plasma (PRP) were isolated from LM-challenged mice and incubated with 100 
μM SFLLRN for 20 mins (A) or 5-20 mins (B). The protein levels of Dkk1 and CD41 in platelets (A) and 
Dkk1 concentrations in plasma (B) were determined by Western blot and ELISA, respectively. (C) Primary 
mouse AEC II was cultured for 4 days and then stimulated with TNFα and IL-1β (20 ng/ml of each) for 24 
hours. Recombinant mouse Dkk1 was added to the cells at indicated concentration for 2 hours. Cell-based 
ELISA was performed to quantify the binding of Dkk1 to the stimulated AEC. (D) mRNA levels of Dkk1 
receptors (KRM1, KRM2, LRP5, and LRP6) were analyzed by Real-time PCR in the TNFα/IL-1β-
stimulated AEC and normalized to control. Data are expressed as means ± s.e.m. from 3 independent 
preparations.  
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Fig. III. 7. Dkk1 inhibits Wnt/β-catenin signaling in AEC. E10 cells were transfected with TOPFlash or 
FOPFlash and pRL-TK plasmids for 24 hours and then treated with 200 μM Dkk1 for 24 hours (A) or 
incubated with 200 ng/ml recombinant human Wnt3a or 50% Con_CM or Wnt3a_CM together with 200 
μM Dkk1 for 24 hours (B). Dual-luciferase assay was performed. TOPFlash or FOPflash Firefly luciferase 
activity was normalized to pRL-TK Renilla luciferase activity. The final results were normalized to 
untreated control. Data are expressed as means ± s.e.m. from 3 independent preparations and tested for 
statistical significance by Student’s t-test or ANOVA analysis followed with posthoc Tukey’s test. * p < 
0.05 v.s. Control. **, ***, and #, were represented as p < 0.05. 
3.4.3 Neutralization of Dkk1 attenuates neutrophil infiltration during acute pulmonary 
inflammation 
Blocking of platelet-leukocyte interaction (53), platelet depletion (54), and anti-platelet 
therapy (55,56) are protective in the development of acute lung inflammation. Neutralization of 
Dkk1 was also reported to limit inflammatory bone loss (57). Here we investigated the effect of 
Dkk1 antibody neutralization in alveolar space on the development of acute lung inflammation. 
Neutrophils were the major recruited inflammatory cells into alveolar space in our two-hit acute 
lung inflammation model as revealed by differential immune cell count analysis of BAL (Fig. III. 
8A). Neutralization of Dkk1 intratracheally inhibited neutrophil infiltration into alveoli 
remarkably (Fig. III. 8A). Whole lung myeloperoxidase (MPO) activity, which is considered as a 
marker of neutrophil sequestrations in the lung (58), was also reduced by anti-Dkk1 antibody 
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(Fig. III. 8B). Since Dkk1 is an inhibitor of Wnt/β-catenin signaling (57), our results imply a 
potential role of Wnt/β-catenin signaling in regulating acute lung inflammation. 
 
Fig. III. 8. Intratracheal neutralization of Dkk1 or administration of Wnt3a attenuates neutrophil 
infiltration during LM-induced acute pulmonary inflammation. Mice were intratracheally instilled with 
LPS together with isotype-matched control IgG or function-blocking mAb against Dkk1 (86 µg/mouse) and 
then mechanically ventilated (LM). Mice were also intratracheally co-administered with control (Con_CM) 
or Wnt3a conditional medium (Wnt3a_CM) along with LPS and ventilated. (A) Differential immune cell 
number in BAL was counted. (B) MPO activity in whole lung tissue was measured. Data are expressed as 
means ± s.e.m. (n=5-8 animals). Statistical significance was determined by one-way ANOVA analysis with 
posthoc Tukey’s test. *, **, and # were represented as p < 0.05. 
3.4.4 Administration of Wnt3a blocks ICAM-1/VCAM-1-mediated neutrophils infiltration during 
acute pulmonary inflammation 
We activated Wnt/β-catenin signaling by administration of Wnt3a intratracheally and 
investigate its effect on the development of acute lung inflammation. Compared with control 
conditional medium group (LM+Con_CM), Wnt3a (LM+Wnt3a_CM) significantly reduced the 
recruitment of neutrophils into alveolar space, decreased the total cell number in BAL, and 
attenuated MPO activity in the whole lung tissue (Fig. III. 8A, B).  
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Activation and transmigration of neutrophils are mediated by a series of adhesion 
molecules and chemotactic signaling (1). We moved on to investigate the potential effect of 
Wnt/β-catenin signaling on this process. The mRNA expression of ICAM-1 and VCAM-1 was 
significantly inhibited by Wnt3a in the LM-insulted lungs (Fig. III. 9A and B). This impaired 
synthesis also led to remarkable reduction of sVCAM-1 concentration in BAL of injured lungs 
(Fig. III. 9C). However, the major chemokines (KC, LIX, MCP-1, and MIP-2) involved in 
neutrophils infiltration were not changed by Wnt3a (Fig. III. 9D). 
Wnt/β-catenin signaling was also reported to limit inflammatory functions of 
macrophages by reducing release of TNFα and IL-6 (31,32). Here we observed that IL-6 in BAL 
was markedly reduced after administration of Wnt3a in LM-insulted lungs (Fig. III. 9E) and this 
reduction was also due to attenuated IL-6 mRNA synthesis by Wnt3a (Fig. III. 9F). However, 
mRNA expression and BAL level of TNFα showed no significant difference between Wnt3a-
treated and control mice upon in the LPS+MV challenge (Fig. III. 9D and G). Our results 
revealed a potentially novel mechanism that Wnt/β-catenin signaling utilized to control neutrophil 
infiltration during acute inflammation. 
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Fig. III. 9. Wnt3a reduces the expression of adhesion molecules ICAM-1/VCAM-1 during LM-
induced acute pulmonary inflammation. Mice were intratracheally challenged by LPS together with 
control (Con_CM) or Wnt3a conditional medium (Wnt3a_CM) and then mechanically ventilated (LM). 
mRNA levels of ICAM-1 (A), VCAM-1 (B), and IL-6 (C) in whole lung tissue were measured by Real-
time PCR and were normalized to blank control. (D) Real-time PCR was also performed to analyze mRNA 
levels of other cytokines (IL1β, TNFα, TGFβ, and IL-10) and chemokines (KC, LIX, MCP-1, and MIP-2) 
in LM+Wnt3a_CM mice. Result was normalized to LM+Con_CM mice. Concentrations of sVCAM-1 (E), 
IL-6 (F), and TNFα (G) in BAL were measured by ELISA. Data are expressed as means ± s.e.m. and tested 
for statistical significance by ANOVA analysis with posthoc Tukey’s test. (n=5-8 animals). * and ** were 
represented as p < 0.05. 
3.4.5 Activation of Wnt/β-catenin signaling inhibited TNFα-induced ICAM-1/VCAM-1 
expression 
Both ICAM-1 and VCAM-1 are expressed in AEC and mediate the infiltration of 
immune cells during acute lung inflammation (7-9). To further elucidate the mechanism of 
Wnt/β-catenin signaling-mediated inhibition of ICAM-1 and VCAM-1 expression in injured 
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lungs, we performed in vitro studies using E10 cells (a mouse type I cell line) and cultured 
primary mouse AEC II (AEC I-like cells). TNFα stimulated the expression of VCAM-1 and 
ICAM-1 in a dose- and time- dependent manner in E10 cells (Fig. III. 10A-D) and primary AEC 
I-like cells (Fig. III. 10E, F). Wnt3a strongly reduced both ICAM-1 and VCAM-1 expression 
stimulated by TNFα (Fig. III. 11 and III. 12A-C). On the other hand, Dkk1 displayed the opposite 
effect on the induction of ICAM-1 and VCAM-1 expression (Fig. III. 12A-C). More importantly, 
platelet releasate augmented the TNFα-stimulated ICAM-1 and VCAM-1 expression in primary 
mouse AEC and this augmentation was blocked by Dkk1 neutralization antibody (Fig. III. 12D, 
E). Our results further support the potential implication of platelet-derived Dkk1 in controlling 
ICAM-1 and VCAM-1 expression during acute lung inflammation. 
Fig. III. 10. ICAM-1 and VCAM-1 expressions were stimulated by cytokines in AEC. E10 cells were 
stimulated by different doses of TNFα for 2 hours (A, B), or treated by 100 ng/ml TNFα for indicated time 
points (C, D). Primary mouse AEC II were cultured for 4 days and then stimulated by 20 ng/ml TNFα for 
indicated time (E). mRNA expression of ICAM-1 (A, C, and E) and VCAM-1 (B, D, and E) was 
determined by Real-time PCR with 18S rRNA as a reference, and normalized to untreated cells. (F) 
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Primary mouse AEC II were cultured for 4 days and then stimulated with different doses of TNFα for 24 
hours. Protein expression of ICAM-1, VCAM-1, and T1α (AEC I marker) was measured by Western blot 
using β-actin as a loading control. Data are expressed as mean ± s.e.m. (n=3). Statistical significance was 
determined by one-way ANOVA analysis with posthoc Tukey’s test. * p < 0.05 v.s. Control. 
 
 
Fig. III. 11. Wnt/β-catenin signaling inhibits ICAM-1 and VCAM-1 protein expression in AEC. E10 
cells were pretreated with recombinant human Wnt3a (200 ng/ml) for 24 hours and then stimulated by 
TNFα (20 ng/ml) for additional 24 hours. Protein levels of ICAM-1, VCAM-1, and activated β-catenin 
(ABC) were determined by Western blot using β-actin as an internal control. 
Fig. III. 12. Platelet-derived Wnt antagonist, Dkk1 is implicated in the stimulation of TNFα-mediated 
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ICAM-1/VCAM-1 expression in AEC. E10 cells were incubated with 50% Con_CM or Wnt3a_CM 
together with 200 μM Dkk1 for 12 hours and then stimulated with 20 ng/ml TNFα for 2 hours (A, B) or 24 
hours (C). Platelets were isolated from LM-challenged mice, resuspended in Tyrodes-HEPES buffer, and 
treated by 0.1 U/ml thrombin for 90 mins. Platelet releasate (PR) was collected and added to cultured 
primary mouse AEC together with isotype-matched control IgG or function-blocking mAb against Dkk1 
(10 μg/ml) for 24 hours. After that, mouse AEC was stimulated with TNFα (20 ng/ml) for 2 hours (D, E). 
The mRNA levels of ICAM-1 (A, D) and VCAM-1 (B, E) were measured by Real-time PCR using mouse 
18S rRNA as reference and normalized to control untreated cells. (C) Protein levels of ICAM-1, VCAM-1, 
and activated β-catenin (ABC) were determined by Western blot with β-actin as an internal control. Data 
are expressed as means ± s.e.m. from three independent preparations and tested for statistical significance 
by ANOVA analysis followed with posthoc Tukey’s test. *, **, *** and # were represented as p < 0.05. 
Since Wnt/β-catenin signaling normally regulates the promoter regions of its target genes 
(59), we examined study the effect of Wnt3a on the promoter activities of ICAM-1 and VCAM-1. 
Wnt3a significantly depressed the TNFα-stimulated ICAM-1 and VCAM-1 promoter activities 
(Figure III. 13A, B). The promoters of ICAM-1 and VCAM-1 contain several NF-κB (P50/P65) 
binding sites, which are essential for their activation (12). We future explored whether Wnt3a can 
block NF-κB-mediated ICAM-1 and VCAM-1 expression. By overexpressing P65 in E10 cells, 
the promoter activities of both ICAM-1 and VCAM-1 were remarkably induced and this 
induction was inhibited by Wnt3a (Fig. III. 13C and D). Our results suggested both ICAM-1 and 
VCAM-1 were the target genes of Wnt/β-catenin signaling. 
 
 
 
 
74 
 
 
Fig. III. 13. Wnt/β-catenin signaling inhibits ICAM-1 and VCAM-1 promoter activities in AEC. (A, 
B) E10 cells were transfected with a luciferase expression plasmid containing ICAM-1 or VCAM-1 
promoter along with pRL-TK plasmid for 12 hours, and incubated with 50% control or Wnt3a_CM for 12 
hours, and finally stimulated by 20 ng/ml TNFα for 24 hours. (C, D) E10 cells were incubated with 50% 
control or Wnt3a_CM for 12 hours, and then transfected with pcDNA3.0-based control or p65 
overexpression plasmid, luciferase expression plasmid containing ICAM-1 or VCAM-1 promoter along 
with pRL-TK plasmid. Dual-luciferase assay was performed. The results were expressed as the ratio of 
ICAM-1 (A, B) or VCAM-1 (C, D) promoter-associated Firefly luciferase activity to pRL-TK Renilla 
luciferase activity, and normalized to control. Data were expressed as means ± s.e.m. from three 
independent preparations and tested for statistical significance by ANOVA analysis followed with posthoc 
Tukey’s test. * P<0.05 v.s. Con_CM. 
Functional crosstalk between NF-κB signaling and Wnt/β-catenin signaling has been 
reported to regulate cell response to cytokines (33,36). The same inhibitory effect of Wnt3a on 
NF-κB signaling activity stimulated by TNFα or P65 overexpression was observed in E10 cells 
(Fig. III. 14). However, we cannot detect the physical interaction between β-catenin and P50/P65 
as previously reported (33) (Fig. III. 15). Wnt3a did not have effects on the activation and nuclear 
translocation of P65 upon TNFα stimulation either (Fig. III. 16). 
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Fig. III. 14. Wnt3a suppresses NFκB signaling in AEC. (A) E10 cells were transfected with luciferase 
expression plasmid containing NFκB transcriptional response element along with pRL-TK plasmid for 12 
hours, and incubated with 50% control or Wnt3a_CM for 12 hours, and finally stimulated by 20ng/ml 
TNFα for 24 hours. (B) E10 cells were incubated with 50% control or Wnt3a_CM for 12 hours, and then 
transfected with pcDNA3.0-based control or p65 overexpression plasmid, luciferase expression plasmid 
containing ICAM-1 or VCAM-1 promoter along with pRL-TK plasmid. Dual-luciferase assay was 
performed. The results were expressed as the ratio of NFκB transcriptional response element-associated 
Firefly luciferase activity (representing NFκB signaling activity) to pRL-TK Renilla luciferase activity, and 
normalized to control. Data were expressed as means ± s.e.m. from three independent preparations and 
tested for statistical significance by ANOVA analysis followed with posthoc Tukey’s test.. * P<0.05 v.s. 
Con_CM. 
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Fig. III. 15. No detectable interaction between β-catenin and P65/P50 in AEC. E10 cells were 
incubated with 50% Con_CM or Wnt3a_CM for 12 hours and then stimulated by 20 ng/ml TNFα for 24 
hours. β-catenin (A) and P65 (B) were pulled down from lysed cells by immunoprecipitation and probed 
with indicated antibodies by Western blot. Output was used as positive control. 
Fig. III. 16. Wnt3a does not affect activation and translocation of P65 upon TNFα stimulation of 
AEC. E10 cells were incubated with 50% Con_CM or Wnt3a_CM for 12 hours and then stimulated by 20 
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ng/ml TNFα for indicated time points (A) or 2 hours (B). (A) Protein levels of p-P65 (ser536) and P65 were 
measured by Western blot. (B) Immunofluorescence staining of P65 and β-catenin under indicated 
conditions. Scale bar = 40 µm. 
3.4.6 Activation of Wnt/β-catenin signaling attenuates ICAM-1/VCAM-1-mediated adhesion of 
alveolar macrophages and neutrophils to AEC 
We further explored the functional significance of Wnt/β-catenin signaling-mediated 
inhibition of ICAM-1 and VCAM-1 expression. Both adhesion molecules are essential for 
neutrophil and macrophage adhesiveness (8,9), and facilitate transepithelial migration of 
monocytes upon influenza virus infection (7). We used an in vitro cell culture model to examine 
the adhesion of primary rat alveolar macrophages (AMϕ) or neutrophils to E10 cells. TNFα 
significantly increased the percentage of attached AMϕ or neutrophils to E10 cells (Fig. III. 17A 
and B). These increases were totally eliminated by the immunoblockage with either anti-ICAM-1 
or anti-VCAM-1 antibodies. Furthermore, Wnt3a dramatically reduced the adhesion of both types 
of immune cells to E10 cells. On the other hand, pretreatment by Dkk1 further increased 
attachment of AMϕ or neutrophils to E10 cells. Our results demonstrated a novel and complex 
cellular communication network in alveoli during progression of acute lung inflammation (Fig. 
III. 18). Modulating platelet-derived Wnt antagonist Dkk1 to control neutrophils infiltration could 
represent an intriguing new therapeutic avenue for patients with acute pulmonary inflammation. 
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Fig. III. 17. Wnt/β-catenin signaling reduces ICAM-1/VCAM-1-mediated adhesion of alveolar 
macrophages and neutrophils to AEC. E10 cells were incubated with 50% Con_CM or Wnt3a_CM 
together with 200 μM Dkk1 for 12 hours and then stimulated by 20 ng/ml TNFα for 24 hours (A, B, the 
first 6 bars). E10 cells were incubated with control IgG or blocking mAbs against ICAM-1 or VCAM-1 for 
30 mins, and then stimulated by 20 ng/ml TNFα for 24 hours (A, B, the last 3 bars). Then adhesion of 
freshly isolated alveolar macrophages (AMØ) or neutrophils to E10 cells were assayed. Values were 
presented as a percent of attached AMØ or neutrophils from three independent experiments and tested for 
statistical significance by ANOVA analysis followed with posthoc Tukey’s test. Data were expressed as 
means ± s.e.m. *, **, ***, #, ##, and ### were represented as p < 0.05. 
Fig. III. 18. Implication of platelet-derived Wnt antagonist Dkk1 in ICAM-1/VCAM-1-mediated 
neutrophilic acute pulmonary inflammation. During the initial stage of acute pulmonary inflammation, 
Dkk1 is induced and released from activated platelets. Released Dkk1 diffuses into alveoli, binds to 
alveolar epithelial cells (AEC) and inhibits Wnt/β-catenin signaling, which in turn gives rise to stimulation 
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of ICAM-1/VCAM-1 expression by pro-inflammatory cytokines and mediates the neutrophil infiltration 
into alveoli. Wnt3a can counterstrike with Dkk1 to activate Wnt/β-catenin signaling in AEC and inhibit 
platelet activity as well (88), which consequently limits the promotion of ICAM-1/VCAM-1 expression, 
impairs the neutrophil infiltration, and finally attenuates the development of acute pulmonary 
inflammation. 
3.5 Discussion 
Although great efforts have been spent to understand the mechanism of ALI/ARDS, 
morbidity and mortality of patients are still remain at high level, and formidable challenges 
persist (60,61). Neutrophil is an essential component of the innate immune system and vital to our 
lives. However, inflammatory damage delivered by activated neutrophils also contributes to 
progression of ALI/ARDS (1,5,62). Lung edema and endothelial and epithelial cell injuries 
accompanied by infiltration of neutrophils are broadly accepted as the classic paradigms of 
pulmonary acute inflammation (63). There are also evidences that activated platelets contribute to 
pathologic syndromes of pulmonary inflammation (14,17,18,52). In this study, using both in vitro 
and in vivo models, we demonstrated a novel regulation of neutrophil recruitment by alveolar 
epithelial cells, which were affetced by platelets in acute inflammatory phase of ALI. We 
identified platelet-derived Dkk1 as a key modulator of Wnt/β-catenin signaling in AEC during 
ALI. More importantly, Wnt3a strongly activated Wnt/β-catenin signaling in AEC, inhibited 
ICAM-1 and VCAM-1-mediated neutrophil adhesion, and finally reduced neutrophil infiltration 
into alveolar spaces in acute pulmonary inflammation.  
In this study, we utilized a mouse model in which acute lung inflammation results from a 
combination of low dose intratracheal LPS instillation and noninjurious mechanical ventilation 
(MV) (45). The synergistic interaction between infectious insults and MV contributes to the 
pathogenesis of ALI/ARDS (64).  Priming of the lungs with LPS or live bacteria makes the 
animals more susceptible to mechanical ventilation (65,66). In this “double hit” paradigm, acute 
lung injury develops and is characterized as synergistic increased cytokine release, activated 
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neutrophil transmigration into the lungs, damage of alveolar epithelia cells and loss of vascular 
integrity [51]. 
In the two-hit model of acute lung inflammation, depression of Wnt/β-catenin signaling 
in AEC was accompanied by accumulation of Wnt antagonist Dkk1 and reduction of Wnt 
agonists’ synthesis (Fig. III. 1). The similar phenomenon was also noticed in influenza virus 
pneumonia, bacteria pneumonia and hyperoxic acute lung injury (Fig. III. 1, 3, and 4). Our 
observations are consistent with the previous reports of suppression of Wnt/β-catenin signaling in 
inflammatory lung diseases. In emphysema and COPD patients, dysfunctional repair is associated 
with decreased Wnt/β-catenin signaling (38,42). In asthma patients, several intracellular signaling 
molecules of the Wnt/β-catenin signaling were significantly reduced (32,39).  In mechanical 
ventilation (MV)-insulted and S. pneumoniae -infected lungs, Wnt/β-catenin signaling is also 
inhibited (40,41). On the other hand, up-regulation of Wnt/β-catenin signaling has also been 
demonstrated in resolution stage of acute lung injury (51,67). Wnt/β-catenin signaling is activated 
in AEC II and essential for alveolar epithelium repair following acute injury (25). Interestingly, 
transepithelial migration of neutrophils also activates Wnt/β-catenin signaling in AEC II and 
accelerates the process of repair (24). Activation of Wnt/β-catenin in AEC is likely initialized by 
Wnt7b (68) (Fig. III. 2), which has been shown to activate Wnt/β-catenin signaling in airway 
ciliated epithelial cells following injury (26). All of these studies indicate a dynamic, 
complicated, and subtle response of Wnt/β-catenin signaling in inflammatory lung diseases. 
Considering a great number of Wnt/β-catenin signaling agonists and antagonists are in the pre-
clinical development stage (69), characterizing the role of Wnt/β-catenin signaling will open a 
new window to explore our potential to control these diseases.  
It is not very clear about the relative contribution of selectins (P, E, and L-selectins) and 
other adhesion molecules (VCAM-1, ICAM-1, and JAMs) to the whole infiltration process 
(capture, rolling, adhesion, and transmigration) of inflammatory cells during acute lung 
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inflammation (1,5). Based on ours and several other in vitro studies, VCAM-1 and ICAM-1 are 
able to mediate the adhesion of neutrophils and macrophages to alveolar epithelial cells (8,9). 
They also modulate monocyte transepithelial migration upon influenza virus infection (7). 
However, considering its exclusive expression on the apical surface of AEC (10,70), ICAM-1 is 
unlikely to mediate neutrophils transmigration across the alveolar epithelium from the basolateral 
side in vivo even though adherence of neutrophils to the apical surface of cultured AEC is ICAM-
1 dependent (Fig. III. 17B). Similar complexity is also observed in vivo that inhibition of ICAM-1 
is protective in ALI but ICAM-1 knockout mice display no protective effect (71). Thus, more 
attention is put on VCAM-1 (72,73). Recently, a new function of VCAM-1 was discovered, i.e. 
soluble VCAM-1 shed from AEC I surface behaves as a chemokine to attract neutrophils into 
alveolar space (unpublished results from our lab).  
Wnt/β-catenin signaling has been demonstrated to regulate several inflammatory 
response processes in vitro (32,33,74). However, no information is available regarding its role in 
acute pulmonary inflammation.Wnt3a has anti-inflammatory functions in macrophages by 
reducing TNFα and IL-6 release (31,32). The same attenuated response of IL-6 but not TNFα was 
observed in our two-hit model of acute pulmonary inflammation. Besides, attenuated neutrophil 
infiltration was the major hallmark of activation of Wnt/β-catenin signaling during acute 
pulmonary inflammation (Fig. III. 8A). Previously, it has been found that Wnt/β-catenin signaling 
suppresses VCAM-1 expression by marrow stromal and hematopoietic cells (35). Wnt/β-catenin 
signaling also attenuates transendothelial migration of monocytes (74). Here we successfully 
discovered that both ICAM-1 and VCAM-1 were the potential target genes of Wnt/β-catenin 
signaling in modulating neutrophil infiltration. Using E10 cells and transdifferentiated cells from 
AEC II as in vitro models of AEC I, we confirmed that the transcriptional regulation of Wnt/β-
catenin signaling on VCAM-1 and ICAM-1 expression was through their promoter activities. We 
also observed a functional crosstalk between NF-κB signaling and Wnt/β-catenin signaling that 
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regulates inflammatory response including ICAM-1 and VCAM-1 expression as reported (33,36). 
However, we cannot verify the physical interaction between β-catenin and NF-κB protein 
(P50/65) (33,37) (Fig. III. 15). The detailed mechanism how Wnt/β-catenin signaling regulates 
ICAM-1/VCAM-1 expression still needs further investigation in AEC. 
By far, sFRP1 is the only Wnt antagonist reported to be augmented in inflammatory lung 
diseases including hyperoxic acute lung injury and emphysema (42). The BALs from ARDS 
patients have a reduced capacity to activate Wnt/β-catenin signaling in fibroblasts [109], 
indicating that there is potentially elevation of Wnt antagonists or reduction of Wnt agonists in 
ARDS BALs. From this standing point, elevation of Dkk1 in alveolar region identified in our 
study adds a new layer of information into this field. Recent evidence has already pointed to an 
important role of Dkk1 in development of inflammation diseases such as atherosclerosis, arthritis, 
and pulmonary fibrosis by controlling fracture repair and pulmonary epithelial homeostasis 
(19,28,44). However, it is unclear whether the increased level of Dkk1 actively modulates these 
inflammatory diseases or is a consequence of the inflammatory process (43). Our current study 
suggests a profound role of elevated Dkk1 and subsequent depression of Wnt/β-catenin signaling 
in the pathoprogression of acute lung inflammation by regulating ICAM-1/VCAM-1-mediated 
immune cell infiltration. As a potential therapeutic target, Dkk1 is developed as a serum biomaker 
of inflammatory diseases and cancer patients (75-77). Neutralization therapy targeting Dkk1 has 
also shed light on osteolytic disease patients (43,57). Here we discovered the elevation of Dkk1 in 
both BAL and plasma in animal models of acute lung inflammation (Fig. III. 4). If the same 
scenario can be confirmed in human patients, using Dkk1 neutralization therapy to limit acute 
pulmonary inflammation could reveal a safer way compared to that using Wnt3a to interfere with 
Wnt/β-catenin signaling activity in the lung, since it avoids the aberrant activation of Wnt/β-
catenin signaling, which could lead to fibroproliferation of AEC (51) and eventually pulmonary 
fibrosis or carcinoma (78,79). 
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Acute lung inflammation is associated with increased platelet activation in the blood 
stream and sequestration in pulmonary vascular beds (13,17,18). The classic contribution of 
platelets to the progression of ALI/ARDS is their unique property of aggregation with neutrophils 
or monocytes, amplifying the inflammatory response and disrupting barrier function of 
endothelial cells (14,18,21). Blocking of platelet-leukocyte interaction (53), platelet depletion 
(54,80), and anti-platelets therapy (55,81) are protective in ALI/ARDS. As the major source of 
Dkk1 in the blood (19), platelets are likely the contributor to the Dkk1 in alveolar space 
considering the big difference in Dkk1 levels between BAL and plasma (Fig. III. 4C and E). In 
addition to Dkk1, other platelet products like RANTES and CD40L are found in the alveolar 
spaces (22,44,62). However, for the first time we reported a specific and functional 
communication between platelets and AEC in inflammatory lung diseases. Manipulation of 
platelet function and life cycle by anticoagulants (82,83) or platelet-stimulating agents (84) could 
potentially be utilized to modulate Wnt/β-catenin signaling activity in patients. Interestingly, 
Wnt3a can also negatively regulate platelet function such as adhesion, activation, defense granule 
secretion and aggregation (85). The dual function of Wnt3a in regulating inflammation needs to 
be interpreted carefully.  
The role of platelets in the host response to pathogen invasion is increasingly appreciated 
(86,87). Clinical severe thrombocytopenia is also frequently observed in patients with pneumonia 
(88) and other acute lung inflammatory diseases (89). This was observed in our in vivo lung 
inflammation mouse models (Fig. III. 5A and B). However, how platelets are activated and 
recruited into pulmonary region during pneumonia is still not fully understood (13). With 
functional TLR-4 expression (90,91), platelets can respond to LPS treatment and bacterial 
infection (Fig. III. 5D and E). It is also reported that influenza virus can interact with platelets and 
consequentially induce their activation (92,93) (Fig. III. 5F). Besides, hyperoxia can also induce 
platelet activation and lung sequestration (94). Since T1α protein (podoplanin, AEC I marker) 
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possesses a platelet aggregation-stimulating domain (95,96), a hypothesis that T1α is implicated 
in platelet recruitment and activation following AEC I damage during lung injury was also 
recently proposed (97). Here we provided an additional piece of evidence in our in vivo model of 
influenza viral pneumonia to support this new hypothesis. From the scope of time frame, release 
of T1α into BAL and potentially plasma due to injury of AEC I at 1 dpi (Fig. III. 4G) might be 
able to trigger the sequestration and activation of platelets (Fig. III 5C and  F), and subsequent 
deposition of Dkk1 in the lung start from 2 dpi (Fig. III. 1D). 
Almost all the pharmacologic therapies evaluated in clinical trials have not proven 
effective. Stem cells therapy is emerged as a new hope for the ALI/ARDS patients (98). Both 
bone marrow-derived mesenchymal stem cells (MSC) and induced pluripotent stem (iPS) cells 
have been reported to attenuate ALI/ARDS though improving fluid clearance, reducing 
neutrophil accumulation and augmenting lung repair (99,100). By far, researchers identified 
Keratinocyte Growth Factor (KGF) (101), interleukin 1 receptor antagonist (IL1RN) (102), 
insulin-like growth factor 1(IGF-1) (103), and prostaglandin E(2) (104) as potential paracrine 
factors secreted from the stem cells, which mediate their protective effects. Since Wnt/β-catenin 
signaling is known to be essential to maintain the phenotype and proper function of stem cells 
(26,105), it is worth to explore the potential contribution of Wnt ligands or modulators from stem 
cells in their protective effects in ALI/ARDS.  
In summary, our results demonstrated a novel function of Wnt/β-catenin signaling in the 
regulation of neutrophil infiltration during acute lung inflammation. Platelet-derived Dkk1 was 
identified as the major Wnt antagonist contributed to the depression of Wnt/β-catenin signaling, 
which led to up-regulation of ICAM-1 and VCAM-1 in AEC. Modulation of Wnt/β-catenin 
signaling by Wnt3a or Dkk1 neutralization successfully prevented neutrophil-mediated acute 
pulmonary inflammation. Our study on platelet-derived Wnt antagonist Dkk1 in ICAM-
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1/VCAM-1-mediated neutrophil infiltration opens a new field in the ALI/ARDS research and 
provides insights for future drug development and new therapeutic strategies of exploration. 
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CHAPTER V 
 
 
AXIN1: A NOVEL SCAFFOLD PROTEIN JOINS THE ANTIVIRAL NETWORK OF 
INTERFERON 
 
4.1 Abstract 
Acute respiratory infection by influenza virus is a persistent and pervasive public health 
problem. Antiviral innate immunity initiated by type I interferon (IFN) is the first responder to 
pathogen invasion and provides the first line of defense. We discovered that Axin1, a scaffold 
protein, was degraded during influenza virus infection of mice. We found that Axin1 boosted type 
I IFN response to influenza virus infection through the stimulation of JNK/c-Jun and Smad3 
signaling. Axin1 also interacted with interferon-induced protein with tetratricopeptide repeats 
1/2/3 (IFIT1/2/3), a viral RNA sensor complex. In addition, Axin1 specifically promoted the 
degradation of hnRNP M, a nucleoprotein required for efﬁcient activity of influenza virus 
polymerases, and sequentially EZH2. Axin1 and its chemical stabilizer, XAV939, successfully 
reduced influenza virus replication and protected the mice from influenza virus infection. Thus, 
our study provides new mechanistic insights into the regulation of type I IFN response and 
presents a new potential therapeutics of targeting Axin1 against influenza virus infection. 
Key words: Axin1, influenza virus, interferon, JNK/c-Jun, and Smad3 
4.2 Introduction
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The influenza virus belongs to the Orthomyxoviridae family and is classified into three 
types: A, B and C based on their internal protein sequences (1). With the global pandemic 
potential and up to 500,000 annual deaths worldwide during seasonal epidemics, influenza A 
virus is a major public health concern and causes enormous economic burden (2). Prevention 
relying on vaccination has several limitations, including the lag time for vaccine manufacture and 
the low coverage rate. Considering the increasing level of viral resistance to current anti-influenza 
drugs targeting neuraminidase (NA) or M2 channel (3), it is particularly important to develop 
novel antiviral medicine. 
  Discovered in 1957, Interferon (IFN) is a category of cytokines that can "interfere" with 
viral replication within host cells (4). IFN is now considered as the most potent vertebrate-derived 
agent for mobilizing antimicrobial effector that functions against invasive pathogens (5). Three 
types of IFN has been identified and classified according to the specification of their receptor 
complex (6). Type I interferons (IFNβ, 14 IFNαs, IFNδ, IFNε, IFNκ, IFNο and IFNτ), well 
known for their antiviral properties, mediate the initiation of both innate immune response and 
subsequent adaptive immunity to viruses. Type II interferon (IFNγ) stimulates broad immune 
responses to various pathogens other than viruses. Type III interferons (3 IFNλs) are also known 
to regulate antiviral response and proposed as ancestral type I IFN. It is widely accepted that viral 
attachment and viral dsRNA intermediates accumulating during virus life cycle are the primary 
mediators triggering IFN production, which ultimately results in expression of thousands of IFN-
stimulated genes (ISGs) (OAS1, MX1, and etc.) and limits virus replication (7). 
  In the early phase of infection, Toll-like receptors (TLR), cytosolic RIG-1-like receptors 
(RIG-1 and MDA5), NOD-like receptors, and C-type lectin receptors are major viral sensors 
which can recognize influenza virus (8). Recently, the novel IFN-regulated viral RNA sensor, 
interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) was discovered with a 
substantial antiviral activity (9). Activation of type I IFN expression by these pattern recognition 
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receptors (PRRs) is controlled by multiple transcription factors (TFs) including c-Jun/ATF2 
(AP1), interferon regulatory factor 3/7 (IRF3/7), and p50/p65 (NF-κB) (10). Smad3, as a 
transcription factor,  also enhances type I IFN expression by specifically cooperating with IRF7 
(11). In the later phase of infection, secreted type I IFN stimulates type I IFN receptor 
(IFNAR1/2) in an autocrine and paracrine fashion, which leads to the activation of Janus kinase 
(JAK) – signal transducer and activator of transcription (STAT) pathway, and finally turns on 
cellular antiviral status (12).  
Axin was discovered as a negative regulator of Axis formation in the development of 
mouse embryos (13). Axin proteins, present in two different isoforms (Axin1 and Axin2), act as 
an architectural platform for the degradation of the oncogenic protein β-catenin (14,15). Unlike 
Axin2, Axin1 has, in fact, emerged as a multifunction scaffolding protein for many other 
signaling pathways, including c-Jun-NH2-kinase (JNK) mitogen-activated protein kinase 
(MAPK) signaling, p53 signaling, and transforming growth factor β (TGF-β) signaling (16). 
Axin1 forms a complex with MEKK1/4 and mediates JNK/c-Jun activation through MKK4/7 
(17). Axin1 also promotes Smad3 phosphorylation in response to TGF-β (18), and downregulates 
the negative factor, Smad7, in TGF-β signaling (19). By forming a ternary complex, Axin1 
stimulates p53 via activation of homeodomain-interacting protein kinase-2 (HIPK2) kinase (20). 
These intriguing β-catenin-independent roles of Axin1 suggest its involvement in multiple 
physiological and pathological processes. In the infectious diseases, Axin1 shows an inhibitory 
effect on bacterial Salmonella invasiveness and regulates inflammatory response during the 
infection (21). In addition, silencing of Axin1 up-regulates human immunodeficiency virus type I 
(HIV-1) gene expression and viral replication (22). Recently, XAV939 was discovered to 
specifically inhibit poly(ADP-ribose) polymerase tankyrase1/2 (TNK1/2), which induces 
poly(ADP-ribosyl)ation (PARylation) of Axin1 and in turn promotes its proteasome-mediated 
degradation (23). 
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In this study, we searched for novel host factors essential for influenza virus replication 
and IFN response during viral infection, and explored new antivirals based on the identified 
targets. We first discovered that Axin1 was degraded in a mouse model of influenza virus-
associated pneumonia. We then demonstrated that Axin1 boosted IFN response and inhibited 
influenza virus replication through the activation of JNK/c-Jun pathway and Smad3 signaling. 
We also found the physical interaction between Axin1 and the viral RNA sensor, IFIT1. In 
addition, we found Axin1 specifically associated with two other host proteins, hnRNP M and 
EZH2, which are required for virus replication, and promoted their degradation. XAV939, an 
Axin stabilizer, attenuated influenza viral pneumonia and protected animals from lethal influenza 
virus challenge. Our studies, for the first time, recruited Axin1, the 16-years old scaffold protein, 
into the antiviral network of interferon. 
4.3 Materials and Methods 
4.3.1 Animals 
All male C57BL/6N mice (6 – 8 weeks old) were obtained from Jackson Laboratory (Bar 
Harbor, ME), housed and cared for by the Laboratory Animal Resource Unit operated by the 
Center for Veterinary Health Sciences, Oklahoma State University. Experimental protocols were 
reviewed and approved by the Institutional Animal Care and Use Committee of Oklahoma State 
University. 
4.3.2 Influenza virus 
Influenza virus H1N1 strain A/Puerto Rico/8/1934 was obtained from American Type 
Culture Collection (ATCC, Manassas, VA), amplified in day-9 to day-10 embryonnated SPF 
eggs, and stored at -80
o
C. 
4.3.3 Mouse model of influenza viral pneumonia 
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Male C57BL/6N mice (6-8 weeks of age) were anesthetized with intraperitoneal injection 
of ketamine (80 mg/kg body weight) and xylazine (10 mg/kg body weight), and inoculated with 
influenza virus A/Puerto Rico/8/1934 H1N1 (250 pfu/mouse) intranasally. Mice were weighed 
daily for the evaluation of loss of body weights and clinical signs such as ruffled fur and 
respiratory distress. Animals were sacrificed on days 0 - 7 post infections. Unlavaged lungs were 
homogenized in liquid nitrogen by mortar and pestle, aliquoted and stored at -80
o
C for further 
use. 
4.3.4 BAL analysis 
Lungs were lavaged with 1 ml of normal saline three times. Bronchoalveolar lavages 
(BAL) were centrifuged at 380 g for 10 min at 4
o
C and the supernatants were stored at -80
o
C for 
further analysis. Protein concentrations in BAL were measured by a Bio-Rad protein assay (Bio-
Rad Laboratories, Hercules, CA). Lactate dehydrogenase (LDH) activity in BAL was determined 
by a Cytotoxicity Detection kit (Roche Applied Sciences, Indianapolis, IN) with type III L-lactic 
dehydrogenase (SIGMA, St. Louis, MO) as standards. BAL cells were resuspended in normal 
saline and total cells were counted using a hemocytometer. For differential cell counts, 
cytospinned cells on the glass slides were stained with Wright-Giemsa.  
4.3.5 Histopathology 
Unlavaged lungs were instilled with 4% paraformaldehyde in PBS at 20 cm H2O pressure 
and fixed for 72 hours, embedded in paraffin and sectioned at 4 µm thickness. The sections were 
stained with hematoxylin and eosin and were examined under a light microscope.  
4.3.6 Survival study of lethal dose influenza virus infection 
 Male C57BL/6N mice (6-8 week old) were challenged intranasally with a lethal dose 
(1,000 pfu) of influenza virus A/PR/8/34 H1N1 under anesthesia. XAV939 (SIGMA, St. Louis, 
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MO) was dissolved in dimethyl sulfoxide (DMSO) and given to the mice orally using metal oral 
gavage in a dose of 50 mg/kg mixed with 1% methylcellulose (50 μl/mouse) every day, beginning 
with a day before infection (-1 dpi) and continued until 2 or 4 days post infection. Control 
animals were given vehicle alone in the same formulation. All animals were observed daily for 
body weight loss and clinical signs such as ruffled fur, inactivity and difficulty in breathing.  
4.3.7 Cell culture 
Human embryonic kidney 293 (HEK293), human lung epithelial A549, and Madin-Darby 
canine kidney (MDCK) cells (ATCC, Manassas, VA) were maintained in Earle's Minimal 
Essential Medium (EMEM) complemented with 10% fetal bovine serum (FBS). Human epithelial 
type 2 (HEp2) cells (ATCC, Manassas, VA) were maintained in EMEM complemented with 10% 
FBS, Glutamine, and Non-Essential Amino Acids. E10 cells, a gift from Dr. Mary Williams 
(Boston University, MA), were cultured in CMRL1066 supplemented with 10% FBS and 
Glutamine. Cells were grown at 37°C in a humidified atmosphere containing 5% CO2. 
4.3.8 Primary mouse alveolar epithelial type II cells (AEC II) isolation 
Murine AEC II were isolated from Male C57BL/6N mice (6-8 weeks of age) as described 
previously (24) . Lung was perfused with solution II (0.9% NaCl, 0.1% glucose, 10 mM HEPES, 
1.3 mM MgSO4, 5 mM KCl, , 1.7 mM CaCl2, 0.1 mg/ml streptomycin sulfate, 0.06 mg/ml 
penicillin G, 3 mM Na2HPO4 and 3 mM NaH2PO4, pH 7.4) to clear the blood. AEC II was 
released from the lung by digestion with dispase (250 caseinolytic units/ml, BD Biosciences, 
Franklin Lakes, NJ). Then, the lung was chopped with a Mcllwain tissue chopper, and the lung 
slices were further digested with DNase I (100 µg/ml) for 45 min at 37
o
C with intermittent 
shaking. The digested lung slices were then filtered through 160-, 37- and 15-µm nylon mesh 
sequentially. The filtrate was centrifuged at 250 g for 10 min at 4
o
C. The cell pellet was 
resuspended in Dulbecco's Modifed Eagle's Medium (DMEM) supplemented with 10% FBS and 
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incubated in a 100 mm petridish coated with mouse IgG (75 µg/dish) for 1 hour. The unattached 
cells were spun down at 250 g for 10 min at 4
o
C and resuspended in DMEM containing 10% 
FBS. The isolated AEC II had a purity of 90% as determined by SP-C staining and a viability of 
over 98% as assessed by trypan blue exclusion. AEC II were cultured in 12-well tissue culture 
plates at 1x10
6
 cells/well in DMEM containing 10% FBS, penicillin and streptomycin for 5 days 
before the use. 
4.3.9 Plasmids and transfection 
 pCS2-based OE-GFP (15681), OE-Axin1 (21287) and OE-Axin2 (21279) plasmids were 
obtained from Addgene (Cambridge, MA). All three plasmids have myc-tag. pLKO.1 lentiviral 
vectors carrying shRNA control, shRNA_hnRNP M (1) and shRNA_hnRNP M (2) were 
purchased from Thermo Fisher Scientific (Waltham, MA). TOPFlash and FOPflash reporter 
plasmids were purchased from EMD Millipore (Billerica, MA). Smad3 signaling and ISRE-luc 
reporter plasmids were purchased from QIAGEN (Valencia, CA). pRL-TK Renilla luciferase 
plasmid was obtained from Progema (Madison, WI). HEK293 cells were cultured on 96-well 
tissue culture plates (dual luciferase assay) and 12-well tissue culture plates (all other 
experiments) until 90% confluence and then transfected with proper plasmids using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA).  
4.3.10 In vitro influenza virus infection 
HEK293, A549 and primary mouse AEC II were washed with serum-free complete 
DMEM and infected with influenza virus at a multiplicity of infection (MOI) of 2 in serum-free 
complete DMEM supplemented with 1 μg/ml L-1-tosylamide-2-phenylethyl chloromethyl ketone 
(TPCK)-treated trypsin (SIGMA, St. Louis, MO) for 1 hour. Then cells were changed into fresh 
serum-free complete medium and continually cultured for 2 to 48 hours. 
4.3.11 In vitro respiratory syncytial virus (RSV) infection 
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HEK293 and Hep2 cells were infected with GFP-labeled RSV-A3 at a MOI of 0.1 or 1 in 
complete DMEM for 1 hour as described previously (25). Then cells were changed into fresh 
complete medium and continually cultured for 12 to 48 hours. 
4.3.12 Quantitative real-time PCR 
Total RNA was extracted from cells or lung tissues using TRI-Reagent (Molecular 
Research Center, Cincinnati, OH) and digested with TURBO DNase (Ambion, Austin, TX, USA) 
to remove the genomic DNA contamination. One µg of RNA was reverse-transcribed into cDNA 
using Moloney murine leukemia virus (M-MLV) reverse transcriptase (Invitrogen, Carlsbad, 
CA), random primers, and oligo dT (Promega, Madison, WI). Real-time PCR was carried out on 
7900HT Fast Real-Time PCR System using SYBR Green I detection Master Mix (Eurogentec, 
CA) as described previously (26). The primers were designed using Primer Express® software 
(Applied Biosystems, Foster City, CA), and listed in Table IV. 1. 
Table IV.1. Real-time PCR primer sequences 
 
4.3.13 Western blot 
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The cells and homogenized lung tissue were lyzed in M-PER Mammalian Protein 
Extraction Reagent containing 1% Halt Protease and Phosphatase Inhibitor Cocktail (Pierce, 
Rockford, IL) by Dounce homogenizer followed by sonication and freeze/thaw cycles. The 
proteins were separated in 10% SDS-PAGE and transferred to nitrocellulose membranes. The 
blots were blocked for 1 hour at room temperature with 5% dried milk in Tris-buffered saline 
(10 mM Tris/HCl, 100 mM NaCl and 0.05% Tween; pH 7.5) (TBS-T) and incubated overnight at 
4°C with anti-Axin1 (1:1000, Cell Signaling Technology, Danvers, MA), anti-Axin2 (1:1000, 
Cell Signaling Technology, Danvers, MA), anti-p-JNK1 (1:1000, Cell Signaling Technology, 
Danvers, MA), anti-JNK1 (1:1000, Cell Signaling Technology, Danvers, MA), anti-p-STAT1 
(Tyr 701) (1:1000, Cell Signaling Technology, Danvers, MA), anti-STAT1 (1:1000, Cell 
Signaling Technology, Danvers, MA), anti-p-GSK-3β (S9) (1:1000, Cell Signaling Technology, 
Danvers, MA), anti-GSK-3β (1:2000, BD Transduction Laboratories, San Jose, CA), anti-p-c-Jun 
(1:1000, Cell Signaling Technology, Danvers, MA), anti-c-Jun (1:1000, Cell Signaling 
Technology, Danvers, MA), anti-p-ATF2 (1:1000, Cell Signaling Technology, Danvers, MA), 
anti-ATF2 (1:1000, Cell Signaling Technology, Danvers, MA),  anti-nonO/p54(nrb) (1:1000, 
SIGMA, St. Louis, MO), anti-SFPQ (1:200, Santa Cruz Biotechnology, Santa Cruz, CA), anti-
hnRNP M (1:200, Santa Cruz Biotechnology, Santa Cruz, CA), anti-EZH2 (1:1000, Cell 
Signaling Technology, Danvers, MA), anti-c-myc (1:2000, DHSB, Iowa City, IO),  anti-RSV-M 
protein serum (1:50, Genscript, Piscataway, NJ), anti-RSV-G protein (1:200, Edward Walsh, 
University of Rochester School of Medicine, Rochester, NY) and anti-β-actin (1:2000, SIGMA, 
St. Louis, MO) antibodies. The blots were then rinsed in TBS-T, and incubated for 1 hour at room 
temperature with goat anti-rabbit, or goat anti-mouse secondary antibodies, coupled to 
horseradish peroxidase (1:2000, Jackson Immunoresearch, West Grove, PA). After being washed, 
the blots were developed by SuperSignal West Pico Chemiluminescent Substrate (Pierce, 
Rockford, IL). The densities of bands were quantified by ImageJ software (National Institutes of 
Health, Bethesda, Maryland [http://rsb.info.nih.gov/ij/]). 
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4.3.14 TCID50 assay 
MDCK cells in 96-well plates were infected with serial dilutions (10
-1
 to 10
-7
) of virus 
samples in serum-free complete EMEM containing 1 μg/ml TPCK-treated trypsin for 1 hour. The 
cells were re-fed with the same medium for 4 days. TCID50 values (median tissue culture 
infective dose) were calculated by the method of Reed and Muench (27).  
4.3.15 Immunofluorescence 
A549 cells were cultured on 24-well tissue culture plates. At the end of the experiment, 
the cells were briefly washed with ice-cold phosphate buffered saline (PBS) and fixed with 4% 
paraformaldehyde for 15 min in room temperature. After being washed with PBS again, the cells 
were permeabilized with 0.3% Triton X-100 for 10 min and blocked with 10% FBS for 1 hour at 
room temperature. After being rinsed, the cells were incubated overnight with primary antibodies 
against Axin1 (1:200), nonO/p54(nrb) (1:200), SFPQ (1:50), hnRNP M (1:50), and EZH2 
(1:200). Subsequently, cells were washed with PBS and incubated with Alexa 568-conjugated 
goat anti-mouse and Alexa 488-conjugated goat anti-rabbit IgG (Invitrogen, Carlsbad, CA) for 
1 hour. The nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI, 1:1000, 
Invitrogen, Carlsbad, CA) for 2 min. Images were acquired using a Nikon Eclipse TE-2000 
inverted fluorescence microscope. 
4.3.16 Immunoprecipitation 
Cells were lysed in the M-PER mammalian protein extraction reagent (supplemented 
with 1% Halt phosphatase and proteases inhibitor mixtures). The cell lysate (400 µg of protein) 
was incubated with anti-Axin1 antibody (2 µg) or control rabbit IgG (2 µg, Cell Signaling 
Technology, Danvers, MA) at 4°C for 1 h. Then 5 µl of protein A and 10 µl of protein G-agarose 
beads were added to the mixtures and incubated overnight at 4°C by gentle end-to-end mixing. 
The agarose beads were washed three times with ice-cold PBS. The proteins were eluted by 
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boiling in 1X SDS sample buffer for western blot analysis. 
4.3.17 Statistics analysis 
The results were analyzed by one-way ANOVA followed with posthoc Tukey’s test for 
multiple comparisons of control and treatment groups, or Student’s t-test using GraphPad Prism 
(version 6). Survival rate between groups was analyzed by Mantel-Cox χ2 test on Kaplan-Meier 
probability estimates using GraphPad Prism. All results were reported as mean ± s.e.m. (n=3-8 
for each condition).  
4.4 Results 
4.4.1 Axin1 is degraded during influenza viral pneumonia 
We used a mouse model of viral pneumonia caused by a sub-lethal dose of H1N1 
influenza virus infection (28). Weight loss was noticed on day 1 and markedly increased after day 
5 (Fig. IV. 1A). The same trend was observed in protein concentration (Fig. IV. 1B) and LDH 
activity (Fig. IV. 1C) of BAL, indicating vascular leakage and loss of epithelial-endothelial 
barrier. This observation was also confirmed in histological section (Fig. IV. 1D), in which 
massive immune cell infiltration can be identified. The number of neutrophils in BAL 
significantly increased at Day 3 and persisted until day 7 (Fig. IV. 1E). While macrophage 
numbers were increased from day 5, infiltration of lymphocyte started from day 6 and this may 
represent the transition from innate immunity to adaptive immunity. 
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Fig. IV. 1.  Acute lung inflammation and injury in influenza virus-infected mouse lungs. Mice were 
intranasally inoculated with H1N1 influenza A/PR/8/34 virus (250 pfu/mouse). The lung tissue and BALs 
were collected at 1 to 7 days post infection (dpi). (A) Body weight. (B) BAL protein concentration and (C) 
BAL LDH activity. (D) H&E staining of paraffin sections of lungs. Scale bar=100 μm. (E) Numbers of 
immune cells  in BAL. Values were shown as means ± s.e.m., n=3 
 To assess the viral replication, we further measured viral gene expression including 
hemagglutinin (HA), nucleoprotein (NP) and matrix protein (MP). The expression of all three 
viral genes reached a plateau at day 3 (Fig. IV. 2A), suggesting that the viral load reached 
maximum at day 3. IFN response was initiated at day 1 as indicated by increases in mRNA 
expression of type I and type III IFNs as well as ISGs (Fig. IV. 2B). As a potential antiviral host 
factor, the expression of Axin1 protein, but not mRNA in the whole lung tissue was significantly 
reduced at day 1 (Fig. IV. 3A, B), suggesting that Axin1 is degraded in the lung at an early stage 
of influenza viral pneumonia.   
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Fig. IV. 2. Virus replication and IFN response in influenza virus infected mouse lungs. Mice were 
challenged with H1N1 influenza A/PR/8/34 virus (250 pfu/mouse) intranasally and the lungs were 
collected at 1 to 7 dpi. Relative mRNA expressions of  (A) viral genes (HA, NP, and MP), (B) type I IFN 
(IFNβ1, IFNα1, and IFNα7),  type III IFN (IFNλ1), and ISGs (OAS1, MX1, and IP10) in whole lung 
tissues were measured by Real-time PCR and normalized to 18S rRNA. Results were expressed as Log2 
(Value) and represented as means ± s.e.m., n=3 
 
 
Fig. IV. 3. Axin1 is degraded during influenza pneumonia. Mice were intranasally infected with H1N1 
influenza A/PR/8/34 virus (250 pfu/mouse) and the lungs were isolated at 1 to 7 dpi. (A) Axin1 protein 
levels in harvested lung tissues were measured by Western blot using β-actin as an internal control. (B) 
Relative band intensity of Axin1 was quantified and normalized to β-actin. mRNA expression of  Axin1 in 
the same lung tissues were measured by Real-time PCR and normalized to 18S rRNA. Both results (protein 
and mRNA) were expressed as a ratio to control (0 dpi). Data shown are means ± s.e.m., n=3 
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4.4.2 Axin1 inhibits influenza virus replication through boosting IFN response 
 To evaluate the potential role of Axin1 in regulating influenza virus replication, we 
overexpressed Axin1 or Axin2 in HEK293 cells prior to influenza virus infection. Axin1 but not 
Axin2 inhibited mRNA expression of viral genes (Fig. IV. 4A, B and C) and virus replication 
(Fig. IV. 4D).  
 
Fig. IV. 4. Axin1 inhibits influenza virus replication. HEK293 cells were transfected with OE-GFP, OE-
Axin1, or OE-Axin2 plasmids for 24 hours and then infected with H1N1 influenza A/PR/8/34 virus 
(MOI=2). The cells were collected at 8 to 24 hours post infection (hpi). (A-C) mRNA expression of viral 
genes (HA, NP, and MP) was analyzed by Real-time PCR and normalized to β-actin. (D) Virus titer in the 
culture media (24 hpi) was measured by TCID50 assay in MDCK cells. Values represent means ± s.e.m. of 
three independent experiments and statistical significance determined by one-way ANOVA analysis with 
posthoc Tukey’s test. *P<0.001 v.s. OE-GFP. 
Axin1 successfully boosted type I IFN mRNA expression including IFNβ1 (Fig. IV. 5A), 
IFNα1 (Fig. IV. 5B), and IFNα7 (Fig. IV. 5C). Accordingly, Axin1 also significantly augmented 
the expression of type I IFN-stimulated genes, including OAS1 (Fig. IV. 5D) and MX1 (Fig. IV. 
5E). Axin1 also elevated type III IFN (IFNλ1) synthesis and response (Fig. IV. 6A and B).  
STAT1, the transcription factor essential for turning on ISG expression (29), was activated by 
Axin1 (Fig. IV. 5F). The activity of interferon-sensitive responsive element (ISRE), primarily 
responsible for the constitutive expression of ISGs (30), was notably increased as well (Fig. IV. 
5G). Similarly, Axin1 drastically reduced RSV viral propagation (Fig. IV. 7A) and viral protein 
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synthesis (Fig. IV. 7B) through magnifying IFN response in HEK293 cells (Fig. IV. 7C). These 
results indicated that the cellular anti-viral machinery was turned on by Axin1. 
Fig. IV. 5. Axin1 stimulates type I IFN response during influenza virus infection. HEK293 cells were 
transfected with OE-GFP, OE-Axin1, or OE-Axin2 plasmids for 24 hours and then infected with H1N1 
influenza A/PR/8/34 virus (MOI=2) for indicated times. mRNA expressions of (A-C) type I IFN (IFNβ1, 
IFNα1, and IFNα7) and (D-E) type I IFN-stimulated genes (OAS1 and MX1) (8 hpi) were measured by 
Real-time PCR and normalized to β-actin. (F) Western blot was carried out to determine the protein 
expression of p-STAT1 (Tyr 701) and total STAT1 with and without virus infection (2 hpi). The expression 
of β-actin was used as an internal control. (G) ISRE_Luc and pRL-TK plasmids were transfected into 
HEK293 cells together with OE-GFP, OE-Axin1, or OE-Axin2 plasmids for 24 hours. Cells were then 
infected with H1N1 influenza A/PR/8/34 virus (MOI=2) for 8 hours. Dual-luciferase assay was performed 
and the results were expressed as the ratio of ISRE_Luc Firefly luciferase activity to pRL-TK Renilla 
luciferase activity. Data shown are means ± s.e.m. of three independent experiments and tested for 
statistical significance by ANOVA analysis with posthoc Tukey’s test. *P<0.01 v.s. OE-GFP. 
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Fig. IV. 6. Axin1 elevates type III IFN response during influenza virus infection. OE-GFP, OE-Axin1, 
or OE-Axin2 plasmids were transfected into HEK293 cells. One day after transfection, cells were infected 
with H1N1 influenza A/PR/8/34 virus (MOI=2) for indicated times. mRNA expression of  (A) type III IFN 
(IFNλ1) and (B) type III IFN-stimulated gene (IP10) was measured by Real-time PCR and normalized to β-
actin. Values represent as means ± s.e.ms of three independent experiments.  
 
Fig. IV. 7. Axin1 inhibits RSV replication and boosts IFN response. HEK293 cells were transfected 
with OE-GFP, OE-Axin1, or OE-Axin2 plasmids for 24 hours and then infected with GFP-labeled RSV-A3 
(MOI=1) for indicated times. (A) Green fluoresce image of infected cells. Scale bar=100 μm. (B) Viral 
proteins (G protein and M protein) levels were measured by Western blot in lysed cells with β-actin as a 
loading control. Myc-tagged Axin1, Axin2, and GFP protein levels were also determined using anti-myc 
antibody. (C) mRNA expression of type I IFN (IFNβ1, IFNα1, and IFNα7),  type III IFN (IFNλ1), and 
ISGs (OAS1, MX1, and IP10) (12 hpi) was measured by Real-time PCR with β-actin as a reference gene. 
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Data shown are means ± s.e.m. and tested for statistical significance by ANOVA analysis with posthoc 
Tukey’s test. *P<0.05 v.s. OE-GFP. 
4.4.3 JNK/c-Jun and Smad3 mediate Axin1-stimulated IFN response 
 We further investigated the mechanism of Axin1-mediated stimulation of IFN response. 
Both Axin1 and Axin2 inhibited canonical Wnt/β-catenin signaling assessed by TOPflash assay 
(Fig. IV. 8A). This is consistent with their known function in the β-catenin degradation complex. 
However, since Axin1, but Axin2 induced IFN response, we further examined other cell signaling 
pathways only affected by Axin1, including TGF-β/Smad, JNK/c-Jun, and p53 signaling (16).  
 
Fig. IV. 8. Axin and its stabilizer XAV939 inhibit Wnt/β-catenin signaling. (A) TOPFlash\FOPFlash 
and pRL-TK plasmids were transfected together with OE-GFP, OE-Axin1, or OE-Axin2 plasmids into 
HEK293 cells for 24 hours. (B) A549 cells were transfected with TOPFlash\FOPFlash and pRL-TK 
plasmids for 12 hours and then treated with XAV939 for 24 hours. After that, both HEK293 and A549 cells 
were infected with H1N1 influenza A/PR/8/34 virus (MOI=2) for 12 hours. Dual-luciferase assay was 
performed. TOPFlash or FOPlash Firefly luciferase activity was normalized to pRL-TK Renilla luciferase 
activity. The results were expressed as the ratio of normalized TOPFlash to FOPlash activity. Data shown 
are means ± s.e.m. of three independent experiments and tested for statistical significance by one –way 
ANOVA analysis with posthoc Tukey’s test. # P<0.05 v.s. OE-GFP. * and ** represent P<0.05. 
Axin1 activated JNK/c-Jun pathway by increasing the phosphorylation of both JNK1 and 
c-Jun. However, Axin2 had no effects on these processes. Both Axin1 and Axin2 did not ATF2 
phosphorylation (Fig. IV. 9A and B). Axin1, but not Axin2, also triggered the activation of 
Smad3 signaling (Fig. IV. 9C).  
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 SP600125, a specific JNK inhibitor (31), successfully blocked Axin1-stimulated IFN 
mRNA expression (Fig. IV. 10A-C and 11A), ISG expression (Fig. IV. 10D, 10E, and 11B) and 
ISRE activity (Fig. IV. 10F). SIS3, a specific Smad3 inhibitor (32), exhibits the same inhibitory 
effect on Axin1-elevated anti-viral machinery except IFNβ1 synthesis (Fig. IV. 10A) and MX1 
expression (Fig. IV. 10E). However, only SIS3, but not SP600125 relived Axin1-mediated 
attenuation of influenza virus replication (Fig. IV. 12A-C). This result showed that both JNK/c-
Jun pathway and Smad3 signaling participated in Axin1-stimulated IFN response through 
different mechanisms. 
 
Fig. IV. 9. Axin1 activates JNK/c-Jun pathway and Smad3 signaling. (A) HEK293 cells were 
transfected with OE-GFP, OE-Axin1, or OE-Axin2 plasmids for 24 hours. The protein levels of 
phosphorylated JNK1 (p-JNK), total JNK (JNK), phosphorylated c-Jun (p-c-Jun), total c-Jun (Jun), 
phosphorylated ATF2 (p-ATF2), and total ATF2 (ATF2), were determined by Western blot. (B) Relative 
band intensities of phosphorylated proteins were quantified and normalized to respective total proteins. (C) 
Smad3 signaling reporter and pRL-TK plasmids were transfected together with different doses of OE-GFP, 
OE-Axin1, or OE-Axin2 plasmids into HEK293 cells for 24 hours. Dual-luciferase assay was performed. 
The results were expressed as a ratio of Smad3 signaling reporter Firefly luciferase activity to pRL-TK 
Renilla luciferase activity. Data shown are means ± s.e.m. of three independent experiments, and statistical 
significance determined by one-way ANOVA analysis with posthoc Tukey’s test.   *P<0.01 v.s. OE-GFP. 
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Fig. IV. 10. Inhibition of JNK/c-Jun and Smad3 signaling reduces Axin1-stimulated type I IFN 
response. HEK293 cells were pretreated with 10 µM SP600125 (JNK inhibitor), 10 µM SIS3 (Smad3 
inhibitor), or 0.05% DMSO for 6 hours. The cells were then transfected with OE-Axin1 plasmid for 24 
hours and then infected with H1N1 influenza A/PR/8/34 virus (MOI=2) for indicated times. The mRNA 
expression of (A-C) type I IFN (IFNβ1, IFNα1, and IFNα7) and (D-E) type I IFN-stimulated genes (OAS1 
and MX1) was measured by Real-time PCR and normalized to β-actin. (F) HEK293 cells were pretreated 
with indicated inhibitors and transfected with ISRE_Luc and pRL-TK plasmids together with OE-Axin1 
plasmid for 24 hours. Cells were then infected with H1N1 influenza A/PR/8/34 virus (MOI=2) for 8 hours.  
Dual-luciferase assay was carried out and the ISRE_Luc Firefly luciferase activity was normalized to pRL-
TK Renilla luciferase activity. Data shown are means ± s.e.m. and tested for statistical significance by 
ANOVA analysis with posthoc Tukey’s test. *P<0.05 v.s. OE-Axin1+DMSO. 
 
Fig. IV. 11. Blockage of JNK/c-Jun and Smad3 pathways attenuates Axin1-elevated type III IFN 
response. HEK293 cells were pretreated with 10 µM SP600125 (JNK inhibitor), 10 µM SIS3 (Smad3 
inhibitor), or 0.05% DMSO. 6 hours later, the cells were transfected with OE-Axin1 plasmid for 24 hours 
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and then infected with H1N1 influenza A/PR/8/34 virus (MOI=2) for indicated times. mRNA expression of  
(A) type III IFN (IFNλ1) and (B) type III IFN-induced gene (IP10) was measured by Real-time PCR and 
normalized to β-actin. Values represent as means ± s.e.m of three independent experiments. 
 
Fig. IV 12. Inhibition of Smad3 signaling relives Axin1-mediated attenuation of influenza virus 
replication. HEK293 cells were pretreated with 10 µM SP600125 (JNK inhibitor), 10 µM SIS3 (Smad3 
inhibitor), or 0.05% DMSO for 6 hours. The cells were transfected with OE-Axin1 plasmid for 24 hours 
and then infected with H1N1 influenza A/PR/8/34 virus (MOI=2) for indicated times. mRNA expression of 
viral genes (HA, NP, and MP) were analyzed by Real-time PCR with β-actin as a reference. Values 
represent as means ± s.e.m of three independent experiments. 
4.4.4 Axin1 interacts with a novel viral RNA sensor  
 To continually explore the details on Axin1-mediated activation of IFN response, we 
analyzed the potential physical interactions between Axin1 and classic viral RNA sensors that 
function in the RIG-1-like pathway (8,33,34). Unfortunately, Axin1 didn’t interact with both 
RIG-1 and MDA5 (Fig. IV. 13). Surprisingly, Axin1 was identified to interact with IFIT1/2/3, a 
novel IFN-induced viral RNA sensor complex (9), during influenza virus infection by mass 
spectrometry (Table IV. 2). Our results brought Axin1 into the antiviral network of interferon as a 
scaffold protein. 
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Fig. IV. 13. Axin1 does not interact with viral senors in the RIG-1 pathway. A549 cells were pretreated 
with 20 µM XAV939 or 0.05% DMSO for 24 hours. Cells were then infected with H1N1 influenza 
A/PR/8/34 virus (MOI=2) for 24 hours. Axin1 was pulled down from lysed cells by immunoprecipitation 
and probed with indicated antibodies by Western blot using Axin2 and Smad2/3 as positive controls (16). 
 
Table IV. 2. Physical interaction between Axin1 and IFIT1/2/3 during influenza virus infection. 
HEK293 cells were transfected with OE-GFP or OE-Axin1 plasmids for 24 hours and then infected with 
H1N1 influenza A/PR/8/34 virus PR/8 (MOI=2) for 8 or 24 hours. Liquid chromatography and tandem 
mass spectrometry of protein complexes isolated by immunoprecipitation. Results are represented as 
number of peptides identified. Data are from three experiments and shown are means ± s.e.m.  
4.4.5 XAV939 stabilizes Axin1 and attenuates influenza virus replication in vitro 
 To further validate the role of Axin1 against virus replication, XAV939, a tankyrase 
inhibitor (35), was utilized to stabilize Axin in A549 cells (Fig. IV. 14A and B). Axin1 was not 
degraded in A549 cells during influenza virus infection when XAV939 was present (Fig. IV. 
14B). XAV939 significantly attenuated influenza viral gene expression (Fig. IV. 14C-E) and 
virus replication (Fig. IV. 14F) in A549 cells. XAV939 also notably inhibited influenza viral gene 
expression (Fig. IV. 15A-C) and virus replication (Fig. IV. 15D) in primary mouse alveolar 
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epithelial cells. Accordingly, XAV939 increased IFNα1 (Fig. IV. 15E) and MX1 (Fig. IV. 15F) 
expression during virus infection in primary mouse alveolar epithelial cells. Similarly, XAV939 
dramatically reduced RSV viral protein synthesis (Fig. IV. 16A) and virus replication in HEp2 
cells as well (Fig. IV. 16B). 
 
Fig. IV. 14. XAV939 stabilizes Axin and inhibits influenza virus replication in A549 cells. A549 cells 
were pretreated with 20 µM XAV939 or 0.05% DMSO for 24 hours. Cells were then infected with H1N1 
influenza A/PR/8/34 virus (MOI=2) for indicated times. (A) Immunostaining of Axin1 (Green) with DAPI 
nuclear staining (Blue) after XAV939 treatment. (Scale bar=50 μm). (B) Western blot analysis of the 
indicated protein expression. (C-E) mRNA expression of viral genes (HA, NP, and MP) was analyzed by 
Real-time PCR and normalized to 18S rRNA. (F) Virus titers in the culture media (24 hpi) were measured 
by TCID50 assay in MDCK cells. Values represent means ± s.e.m. of three independent experiments and 
statistical significance determined by Student’s t-test. *P<0.001 v.s. DMSO. 
 
 
114 
 
 
Fig. IV. 15. XAV939 reduces influenza virus replication and augments type I IFN response in 
primary mouse alveolar epithelial cells. Primary mouse alveolar epithelial cells were pretreated with 20 
µM XAV939 or 0.05% DMSO for 24 hours. Cells were then infected with H1N1 influenza A/PR/8/34 
virus PR/8 (MOI=2) for indicated times. (A-C) mRNA expression of viral genes (HA, NP, and MP) were 
analyzed by Real-time PCR and normalized to 18S rRNA. (D) Virus titer in the culture media (24 hpi) was 
measured by TCID50 assay in MDCK cells. mRNA expression of  IFNα1 (E) and MX1 (F) (12 hpi) were 
measured by Real-time PCR and normalized to β-actin. Data shown are means ± s.e.m. of three 
independent experiments and tested for statistical significance by one–way ANOVA analysis with posthoc 
Tukey’s test or Student’s t-test . *P<0.05 v.s. DMSO. 
 
Fig. IV. 16. XAV939 reduces RSV replication. Hep2 cells were pretreated with 20 µM XAV939 or 
0.05% DMSO for 24 hours. Cells were then infected with GFP-labeled RSV-A3 (MOI=0.1 or 1) for 48 
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hours. (A) Viral proteins (G protein and M protein) expression was measured by Western blot in lysed cells 
with β-actin as a loading control. (B) Green fluorescence image of infected cells. Scale bar=100 μm. 
4.4.6 XAV939 protects mice from lethal influenza virus challenge 
 To evaluate the therapeutic application of Axin1 as a novel target to limit virus infection, 
XAV939 was further tested as a potential antiviral agent in vivo (Fig. IV. 17A). Oral 
administration of XAV939 for 24 hours successfully stabilized Axin1 in the mouse lung as 
previously reported (36) (Fig. IV. 17B). XAV939 also significantly attenuated influenza virus 
replication in vivo (Fig. IV. 17C) and dramatically improved the survival rate of animals 
challenged with a lethal dose of H1N1 influenza A/PR/8/34 virus at 1,000 pfu/mouse with two 
different strategies of XAV939 administration (-1 to 2 dpi or -1 to 4 dpi) (Fig. IV. 17D).  
 
Fig. IV. 17. XAV939 stabilizes Axin1 and protects mice from lethal influenza virus challenge. Mice 
were challenged intranasally with a lethal dose (1,000 pfu) of H1N1 influenza A/PR/8/34 virus. XAV939 
treatment was given orally and daily, beginning with one day before infection (-1 dpi) and continued until 2 
(XAV939 (I)) or 4 (XAV939 (II)) days post infection. Control animals received vehicle alone. (A) The 
illumination of experimental design. (B) Axin1 protein expression in the lungs after a 24-hour treatment of 
XAV939. (C) Virus titer in the homogenized infected lungs at 2 dpi was measured by TCID50 assay in 
MDCK cells and normalized to total protein amount (n=5). Data shown are means ± s.e.m. and tested for 
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statistical significance by Student’s t-test. (D) Survival rate (10-11 mice/group). Mantel-Cox χ2 test on 
Kaplan-Meier survival data was used to compare the survival rate between groups.  
4.4.7 Axin1 interacts with the host factors involved in antiviral response  
As a scaffold protein, Axin1 could potentially interact with other host factors and 
incorporated into other cellular antiviral machinery against influenza virus replication. Besides 
regulating IFN response, Axin1 was also found to co-localized and interacted with four other host 
factors (nonO/p54(nrb), SFPQ, hnRNP M, and EZH2) that are involved in antiviral response (37-
39) (Fig. IV. 18A, B). More interestingly, all of these identified interactions are lost during 24-
hour influenza virus infection (Fig. IV. 18B).   
 
Fig. IV. 18. Interactions between Axin1 and NonO/p54, SFPQ, hnRNP M and EZH2 are lost during 
influenza virus infection. (A) Double immunostaining of Axin1 (Red) and NonO/p54, SFPQ, hnRNP M 
and EZH2 (Green) with DAPI nuclear staining (Blue) in A549 cells. Scale bar=10 μm. (B) A549 cells were 
pretreated with 20 µM XAV939 or 0.05% DMSO for 24 hours. Cells were then infected with H1N1 
influenza A/PR/8/34 virus (MOI=2) for 24 hours. Axin1 was pulled down from lysed cells by 
immunoprecipitation and probed with indicated antibodies by Western blot. 
XAV939 stimulated the degradation of all four proteins (Fig. IV. 19A). Axin1 and Axin2 
both facilitated the degradation of nonO/p54(nrb) and SFPQ during influenza virus infection (Fig. 
IV. 19B). However, Axin1 specifically promoted the degradation of hnRNP M and EZH2 during 
viral infection (Fig. IV. 19B). Interestingly, knock down of hnRNP M led to loss of EZH2 (Fig. 
IV. 20). This result together with a previous report implied that hnRNP M and EZH2 could be 
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essential for influenza virus replication (40). More detailed studies need to be carried out to 
explore the mechanism of both proteins in regulating influenza virus life cycle. 
 
Fig. IV. 19. Axin1 specifically facilitates degradation of hnRNP M and EZH2 during influenza virus 
replication. (A) A549 cells were pretreated with 20 µM XAV939 or 0.05% DMSO for 24 hours. Cells 
were then infected with H1N1 influenza A/PR/8/34 virus (MOI=2) for indicated times. (B) HEK293 cells 
were transfected with OE-GFP, OE-Axin1, or OE-Axin2 plasmids for 24 hours and then infected with 
H1N1 influenza A/PR/8/34 virus (MOI=2) for 2 hours. Western blot was carried out to check the indicated 
protein expression using β-actin as an internal control. 
 
Fig. IV. 20. Loss of hnRNP M leads to degradation of EZH2. HEK293 cells were transfected with 
plasmids carrying two different shRNAs against hnRNP M or control shRNA for 72 hours. Western blot 
was performed to measure the protein expression of both hnRNP M and EZH2 in the lysed cells with β-
actin as a loading control. 
4.5 Discussion 
The mortality rate of pneumonia and influenza virus infection continually declined 
through the 20
th
 century because of the improvement of anteceded medical strategies for the 
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prevention of lung infections (2,41). However, acute pulmonary infection remains a substantial 
concern as acute lower respiratory infections still cause the most deaths and are the largest 
economic burden among all infectious diseases worldwide (2,42). Unlike respiratory syncytial 
virus (RSV), which is the major cause of respiratory illness (bronchiolitis or pneumonia) in young 
children (43), influenza virus has the ability to span on patients of all ages even adults (44). In our 
study, we discovered the protective effect of Axin1 and its stabilizer XAV939 on influenza virus 
and RSV infections. By interacting with IFIT1/2/3, a novel RNA virus sensor complex, Axin1 
boosted antiviral type I IFN response through augmenting JNK/c-Jun and Smad3 signaling. 
Axin1 also interacted and promoted the degradation of hnRNP M and EZH2, two essential host 
factors for influenza virus replication, sequentially (Fig. IV. 21). Targeting Axin1 to regulate IFN 
response could potentially developed as broad-spectrum antivirals. 
 
Fig. IV. 21. Axin1 joins the antiviral network of interferon. Axin1 interacts with the viral RNA sensor 
IFIT1/2/3 to initiates the type I IFN response against influenza virus replication through JNK/c-Jun and 
Smad3/IRF3 signaling. Axin1 also specifically promotes the sequential degradation of hnRNP M and 
EZH2, two essential host factors supporting influenza virus replication. As such, XAV939, Axin stabilizer, 
could be used as a potential broad-spectrum inhibitor against virus infection. 
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A unique feature in signaling transduction is that several different pathways depend on a 
group of crucial regulators referred to as scaffolds, which bind simultaneously several 
components in the same or different signaling routes and augment specificity` and efficacy during 
signal transduction (19). By serving as a multidomain scaffold, Axin1 coordinates several 
different protein complexes involved in regulating TGF-β/Smad, JNK/c-Jun, and p53 signaling 
(16). In this study, we found that both transcription factors, c-Jun and Smad3, were activated by 
Axin1 to facilitate IFN response. Instead of classic viral RNA sensors, RIG-1 and MAD5 (33,34), 
Axin1 was detected through a newly identified viral 5' triphosphate double stranded RNA (5’ppp-
dsRNA) sensor complex IFIT1/2/3, which initiates IFN-mediated antiviral response (9). This 
positive-regulated signaling cycle mediated by Axin1 and IFIT1/2/3 (ISGs) remains to be 
determined (45).   
Both IRF3 and IRF7 are well known to be essential for the cytosolic pathway-mediated 
type I IFN induction (46,47). Because Smad3 can only interact and cooperate with IRF7 (11), we 
have this special opportunity to explore the relative contribution of IRF3 and IRF7 to the 
activation of type I IFN synthesis and ISGs expression. In the recently established “two-step” 
model (10), IRF3 is primarily responsible for the initiation of IFNβ1 expression. IRF7 is then 
induced by IFNβ1 and comes into play in the later phase for IFNαs induction. Our results support 
this hypothesis because SIS3 (Smad3 inhibitor) only inhibited Axin1-induced expression of IFNα 
but not IFNβ1. In the same experiment setting, we also discovered an obvious difference between 
IRF3 and IRF7 in regulating OAS1 and MX1 expression (Fig. IV. 10D and E) as previously 
reported (48). As we expected, SIS3 successfully inhibited Axin1-mediated attenuation of virus 
replication. This result also partially confirmed that the effect of Axin1 on virus replication is 
through regulating type I IFN response.  
In the promoter region of type I IFN genes, the assembly of ATF2 and c-Jun (AP1) is 
required for their substantial expression (49). In this study, we found that Axin1 only activated 
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JNK/c-Jun pathway without affecting p38/ATF2 activity. Unlike SIS3, SP600125 (JNK/c-Jun 
pathway inhibitor) failed to reverse Axin1-inhibited virus propagation even though it inhibited the 
Axin1-agumented type I IFN responses. This mismatch is probably because JNK/c-Jun pathway 
inhibitor itself can suppress influenza viral RNA and protein synthesis, and override the effect of 
attenuated type I IFN responses on virus replication (50).  
Type I and Type III IFN activate the same STAT heterodimer (STAT1/2) to induce ISGs 
from IFN-stimulated response elements (ISREs) (5,51). Axin1 significantly stimulated STAT1 
and subsequent ISREs activity. Our results reveal the same mechanism of Axin1 on regulating 
both Type I and Type III IFN synthesis because SIS3 and SP600125 exhibit the same inhibitory 
effect in both scenarios.  
Axin2 did not amplify the type I IFN response and affect virus replication. The similar 
effect was also observed in bacterial Salmonella infection (21). Considering that both Axin1 and 
Axin2 inhibited Wnt/catenin signaling (14) (Fig. IV. 8A), the activation of type I IFN synthesis 
by Axin1 is obviously not through the manipulation of Wnt/catenin signaling. Influenza virus 
infection also had no effect on Wnt/catenin signaling (Fig. IV. 8B). However, the activation of 
Wnt/catenin signaling by Wnt3a dramatically promotes virus replication through an unknown 
mechanism in vitro and in vivo (Fig. IV. 22). On the other hand, Wnt3a has been reported to 
amplify IFN response (52) potentially through interaction between β-Catenin and LRRFIP1 (53), 
another cytosolic viral RNA sensor. However, this cannot explain the remarkable effect of 
Wnt/catenin signaling on virus amplification. Instead, it implicates the induction of type I IFN 
synthesis by Axin1 through JNK/c-Jun and Smad3 signaling is intensive enough to override the 
potential negative effect of suppressed Wnt/catenin signaling on ISREs response. Considering the 
side effect of type I IFN on sensitizing host to secondary bacterial pneumonia post influenza 
infection (54) and promoting cell death (55) as Axin1 normally involved (56), more detailed 
studies need to be carried out in vivo. 
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Fig. IV. 22. Activation of Wnt/β-catenin signaling amplify influenza virus replication. (A) E10 cells 
were pretreated with 250 ng/ml rhWnt3a, 25 mM LiCl, 50% Con_CM, or 50% Wnt3a_CM for 24 hours. 
Cells were then infected with H1N1 influenza A/PR/8/34 virus PR/8 (MOI=2) for 18 hours. (B) Mice were 
inoculated with influenza virus A/Puerto Rico/8/1934 H1N1 (250 pfu) intranasally. 50µl 10X Wnt3a_CM 
or Con_CM was given to the mice 4 hours before infection and 2 days post infection intranasally. Lungs 
were isolated on day 5 post infections. (n=4/group). mRNA expression of viral genes (HA, NP, and MP) 
were analyzed by Real-time PCR with 18S rRNA as a reference. The results were normalized to control 
and represent as means ± s.e.m. Statistical significance was tested by one –way ANOVA analysis followed 
by posthoc Tukey’s test. *P<0.01 v.s. Control. #P<0.05 v.s. Con_CM. 
Axin1 has been reported to be the rate limiting factor for the β-catenin destruction 
complex assembly due to its extremely low basal expression (57). This unique feature and its 
antiviral property make it a perfect host factor to be stabilized against virus infection. In this 
study, we utilized XAV939 to stabilize Axin1 and evaluated its potential antiviral activity against 
influenza virus in vitro and in vivo. XAV939 has previously been reported to inhibit herpes 
simplex virus replication (58). Oral administration of XAV939 successfully stabilizes Axin1 in 
the lung as previously reported (59). More importantly, XAV939 successfully reduces influenza 
virus replication in vitro and in vivo, and protects the mice from lethal influenza virus infection.  
IFN exerts significant protection on limiting respiratory virus infection including highly 
pathogenic H5N1 influenza A virus infection in animals (60,61). However, viruses can block 
nearly all aspects of IFN regulatory pathway through intimate interplay to avoid the compromise 
of virus replication (62). In our study, we found that Axin1, as an antiviral mediator, was 
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degraded in influenza viral pneumonia in vitro but not in vitro. This could be due to complicated 
systemic response to virus infection, sophisticated paracrine signaling, and an adequate set of 
protein degradation machinery in vivo. Several other components of ubiquitin-proteasome 
pathway (USP34 and RNF146) and small ubiquitin-related modifier (SUMO) are also involved in 
regulating homeostasis of Axin1 (63-65). Targeting these molecules to stabilize Axin1 could also 
be potentially utilized against virus replication. 
Functional genomics and proteomics have been given a great appreciation to provide a 
broad view of virus-host interactions (66,67). Recently, a quantitative proteomics study reveals 
reduced levels in paraspeckle proteins splicing factor proline-glutamine rich (SFPQ) and Non-
POU domain-containing octamer-binding protein (nonO/p54(nrb)) in influenza A virus-infected 
cells (68). These proteins are frequently associated with heterogeneous nuclear ribonucleoprotein 
M (hnRNP M) in defined nuclear structure to influence splicing patterns of specific pre-mRNAs 
(69). A recent study further demonstrates that SFPQ, but not nonO/p54(nrb), is a host factor 
specifically required for influenza virus multiplication by increasing the efficiency of viral 
mRNA polyadenylation and transcription of viral RNPs (70). hnRNP M also interacts with 
influenza virus polymerase complex (71) and is essential to maintain the efﬁcient activity of both 
H1N1 and H5N1 influenza virus polymerases (40). Since Axin1 and Axin2 both promoted 
degradation of SPFQ and nonO/p54(nrb), these two proteins less likely contribute to Axin1-
specific antiviral property. More importantly, Axin1 specifically induced degradation of hnRNP 
M and EZH2, histone-lysine N-methyltransferase, sequentially. Recent data demonstrated that 
Axin1 is a central coordinator of c-Myc degradation through coupling to GSK3β signaling (72). 
Activation of GSK3β during influenza virus infection shown in our results (Fig. IV. 14B) could 
also be implicated in Axin1- mediated degradation of these host factors. 
Taking advantage of host cellular signaling to support viral replication by influenza virus 
is very effective. However, this dependency might also be utilized to develop novel antiviral 
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approaches. Our work here is an example of translating this information into potential 
therapeutics. We discovered a novel function of Axin1 in limiting virus infection and 
incorporated this scaffold protein into the antiviral network of interferon. 
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CHAPTER V 
 
 
SUMMARY AND CONCLUSION 
 
As one of the major unmet medical needs and public health priorities, ALI/ARDS is 
threatening the human lives of around 200,000 patients annually in US. Understanding the key 
hemostatic, inflammatory, and host defense response in ALI/ARDS is critical for continually 
reducing its mortality and mobility.  
The emerging role of alveolar epithelium in the pathogenesis and resolution of 
ALI/ARDS has been increasingly appreciated. Loss of alveolar epithelium integrity leads to the 
increased permeability and influx of protein-rich edema fluid. However, a comprehensive 
understanding of the mechanism of alveolar epithelium injury involved in ALI/ARDS is still 
lacking. Developmental signaling such as Wnt/β-catenin signaling has been studied in the 
resolution and repair stage of ALI/ARDS and dysregulated matrix remodeling during pulmonary 
fibrosis. This is the first study which identified a new role of Wnt/β-catenin signaling in 
regulating alveolar epithelium injury in crosstalk with P2X7R-mediated purinergic signaling 
during the acute phase of ALI/ARDS.  
Acute inflammation, thrombosis, and activation of coagulation cascade all contribute to 
the initiation and exacerbation of ALI/ARDS. However, the detail regulation of proinflammatory 
cells (neutrophils, monocytes, macrophages, and others) migration, and dysregulation of cells 
involved in hemostasis and thrombosis (platelets) are still not clear. Here we demonstrate a novel
 
 
129 
 
regulation of neutrophil recruitment by alveolar epithelial cells, which are mediated by ICAM-1 
and VCAM-1, controlled by Wnt/β-catenin signaling, and affected by platelets in acute 
inflammatory phase of ALI. We identified platelet-derived Dkk1 as a key modulator of Wnt/β-
catenin signaling in alveolar epithelial cells. We also provided the proof-of-concept results of 
using Wnt3a or Dkk1 neutralization antibody to reduce neutrophil infiltration and acute 
inflammation in ALI/ARDS.  
Viral lower respiratory tract infection is the most frequent cause of ALI/ARDS. Due to 
the high mutation rate of influenza virus, drug-resistant strains are continually emerging against 
conventional antivirals which target viral proteins. Identifying novel host factors with antiviral 
property can significantly benefit the development of new antiviral drug to limit future pandemic 
outbreaks. In this study, we reported for the first time that Axin1 boosted type I IFN response to 
influenza virus infection through the stimulation of JNK/c-Jun and Smad3 signaling. Axin1 and 
its chemical stabilizer, XAV939, successfully inhibited influenza virus replication and protected 
mice from influenza virus infection. 
In summary, our study on crosstalk of P2X7R-mediated purinergic signaling and Wnt/β-
catenin signaling in modulating alveolar epithelium integrity, and platelet-derived Wnt antagonist 
Dkk1 in ICAM-1/VCAM-1-mediated neutrophil infiltration open new fields in the ALI/ARDS 
research and provides insights for future drug development. We also identified Axin1 as a new 
member in the antiviral network of interferon. Novel antiviral approaches can be developed by 
targeting Axin1-mediated host defense response. 
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